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Literature review 
Introduction 
Sub-Saharan Africa is overwhelmed by dual epidemics of human immunodeficiency virus (HIV) and 
tuberculosis (TB) infection. Non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based 
antiretroviral therapy (ART) is recommended for first-line treatment in adult HIV treatment 
programmes in resource-limited settings [1]. Many South African HIV-infected patients initiate ART 
while on TB treatment, 38 percent in one local study [2]. In addition, although ART reduces the 
incidence of TB, incidence in patients on ART is higher than in the HIV uninfected population [3], 
therefore incident TB on ART requiring concomitant treatment is very common.  Efavirenz is 
regarded as the NNRTI of choice for TB co-infected patients [1] as outcomes are superior compared 
to those achieved with nevirapine-based ART [4] and concomitant TB treatment does not 
significantly reduce efavirenz concentrations [5]. However nevirapine is cheaper than efavirenz and 
is used extensively used in lower income countries with limited access to efavirenz [1].  Data 
characterising the extent to which concomitant rifampicin-based TB treatment decreases nevirapine 
plasma concentration therefore remain important. 
Nevirapine is metabolised by cytochrome P450 (CYP) isoenzymes, predominantly CYP3A4 and 
CYP2B6 [6]. Rifampicin potently induces many genes controlling drug metabolism and transport, and 
up-regulates expression of several CYP isoenzymes, including CYP3A4 [7]. Rifampicin may therefore 
reduce concentrations of many concomitantly administered medicines, including nevirapine, which 
is a substrate of CYP3A4 [6]. Isoniazid, an inhibitor of CYP3A isoenzymes, may increase 
concentrations of concomitantly administered medicines [8, 9]. When isoniazid is administered 
together with rifampicin in TB treatment regimens, this may modify the effect of rifampicin on the 
metabolism of concomitantly administered nevirapine.  
Reduction in nevirapine concentrations is of clinical importance as it may result in treatment failure, 
requiring an ART regimen switch. This is particularly problematic in resource-limited settings where 
ART regimen options are limited and second-line ART is considerably more expensive than first-line 
ART. A cohort study conducted in Cape Town in 2008 (n=2035) showed inferior treatment responses 
in patients on rifampicin-based TB treatment who were initiated on nevirapine-based ART, when 
compared with patients initiated on efavirenz-based ART [4].  At 6 months 16.3% (95% CI 10.6, 
23.5%) of patients initiated on nevirapine failed virologically, compared to 8.3% (95% CI 6.7, 10.0%) 
of patients initiated on efavirenz [4]. It is likely that the difference in rates of virological failure result, 
at least in part, from sub-therapeutic nevirapine concentrations due to concomitant rifampicin-
based TB treatment. Reduction in concentrations may be particularly important at the time of 
initiation of ART. It is standard practice to administer a lower “lead-in” dose of 200 mg nevirapine 
daily for 2 weeks, before nevirapine auto-induction is established. Studies in Malawi and Thailand 
found that when nevirapine was dosed at 200 mg daily for lead-in together with rifampicin-based TB 
treatment, 59% and 79% of participants respectively had sub-therapeutic nevirapine concentrations 
during lead-in [10, 11]. This is probably because rifampicin had already fully induced nevirapine 
metabolism. Nevirapine was initiated with lead-in dosing in the Cape Town cohort described above, 
and the investigators hypothesised that this was the cause of inferior outcomes [4]. Omission of 
lead-in dosing is now recommended when nevirapine is administered together with rifampicin-
based TB treatment [1]. However, the CARINEMO randomised controlled trial (RCT) of efavirenz-
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based versus nevirapine-based ART with TB treatment in HIV-TB co-infected patients in 
Mozambique, which omitted lead-in dosing for nevirapine, also showed poorer outcomes in the 
nevirapine arm [12]. The CARINEMO study set out to determine if nevirapine was non-inferior to 
efavirenz, with a non-inferiority margin of 10%. In the intention to treat analysis nevirapine was 
inferior to efavirenz:  60% of patients on nevirapine and 68.4% of patients on efavirenz had a viral 
load of below 50 copies/mL at 6 month (difference 8.4%, 1-sided 95% CI 15.0%) [12].  
This is a review of studies exploring the pharmacokinetic interaction between nevirapine and 
rifampicin-based TB treatment. In addition, studies exploring nevirapine metabolism are reviewed. 
The data collection for the research project presented in this thesis took place in 2005 and 2006, and 
the work was published in 2008 (Cohen K, van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith 
PJ, Maartens G. 2008.  Effect of rifampicin-based antitubercular therapy on nevirapine 
plasma concentrations in South African adults with HIV-associated tuberculosis. J 
Antimicrob Chemother  61, 389–393)[13].  In this review I will present the data that were available at 
the time of publication of our study, and the data that have been published since, in order to place 
my work in context with subsequent advances in the field. In addition, I will discuss the gaps in 
current knowledge, and questions requiring further research.  
In this review, I have focused on data characterising the pharmacokinetic interaction. I have 
therefore not included data on safety and efficacy outcomes with co-administration of nevirapine-
based ART and rifampicin or rifampicin-based TB treatment presented in reports on the included 
studies.   
The most recent antiretroviral therapeutic drug monitoring (TDM) guidelines, published in 2006, 
recommend a target nevirapine trough concentration (Cmin) of greater than 3 mg/L, as evidence to 
date suggests that there is an increased risk of virological failure below this cut-off [14-17]. Previous 
TDM guidelines  suggested targets of 3.1 mg/L and 3.4 mg/L, and these values are used as the cut-off 
to define therapeutic concentrations in some of the earlier studies discussed below [15]. In my 
review of interaction studies, I have focused on the effect of rifampicin or rifampicin-based TB 
treatment on Cmin, as this is the parameter that has been correlated with efficacy of nevirapine.  
However, area under the curve (AUC) characterises total drug exposure, and assessing changes in 
AUC will more accurately characterise the magnitude of a drug interaction. Where AUC has been 
calculated and reported, these results are also presented. 
Objectives of literature review 
The objectives of this literature review are: 
1. To review studies exploring the effect of rifampicin or rifampicin-based TB treatment on 
nevirapine concentrations. 
2. To review studies exploring metabolism of nevirapine. 
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Methods 
Definitions 
Rifampicin-based TB treatment: Rifampicin administered in combination with isoniazid, with or 
without concomitant pyrazinamide and ethambutol. 
Nevirapine-based ART: Nevirapine administered in combination with two nucleoside reverse 
transcriptase inhibitors (NRTIs). 
Inclusion criteria 
For studies exploring nevirapine metabolism, inclusion criteria are as follows: 
• In vivo or in vitro study in humans or human tissue  
• Measurement of nevirapine metabolite concentrations 
For studies exploring the interaction between nevirapine and rifampicin or rifampicin-based TB 
treatment, inclusion criteria are as follows:  
• Participants either healthy volunteers or  HIV-infected patients 
• Adult participants (>=18 years old) 
• Administered nevirapine with either rifampicin or rifampicin-based TB treatment. 
• Nevirapine concentrations measured both on and off rifampicin or rifampicin-based TB 
treatment.  
o This includes within patient comparisons (with at least one sampling occasion in the 
presence of rifampicin or rifampicin-based TB treatment, and one sampling occasion 
without rifampicin or rifampicin-based TB treatment) , and between patient 
comparisons (where nevirapine concentrations are compared between a group of 
participants on rifampicin or rifampicin-based TB treatment, and a group without 
rifampicin or rifampicin-based TB treatment.) 
Studies with both intensive and sparse pharmacokinetic sampling are included. Non-compartmental 
analyses, as well as analyses performed using population methods are included. 
Search strategy 
I searched the electronic journal database Pubmed. Nevirapine was registered with United States 
Food and Drug Administration (FDA) in 1996, so the search included all articles published from 1990 
onwards in order to capture any articles published before nevirapine registration. Pubmed search 
terms were as follows: 
 ("nevirapine"[MeSH Terms] OR "nevirapine"[All Fields]) AND (("rifampin"[MeSH Terms] OR 
"rifampin"[All Fields] OR "rifampicin"[All Fields]) OR ("rifampin"[MeSH Terms] OR "rifampin"[All 
Fields]) OR ("isoniazid"[MeSH Terms] OR "isoniazid"[All Fields]) OR ("tuberculosis"[MeSH Terms] OR 
"tuberculosis"[All Fields]) OR ("antitubercular agents"[MeSH Terms] OR ("antitubercular"[All Fields] 
AND "agents"[All Fields]) OR "antitubercular agents"[All Fields] OR "antitubercular"[All Fields] OR 
"antitubercular agents"[Pharmacological Action]) OR pharmacokinetic[All Fields] OR ("drug 
interactions"[MeSH Terms] OR ("drug"[All Fields] AND "interactions"[All Fields]) OR "drug 
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interactions"[All Fields] OR ("drug"[All Fields] AND "interaction"[All Fields]) OR "drug interaction"[All 
Fields]) OR metabolite[All Fields] OR hydroxynevirapine[All Fields] OR 12-hydroxynevirapine[All 
Fields]) AND ("1990/01/01"[PDAT] : "2012/12/31"[PDAT]) 
In addition, I searched conference proceedings from the Conferences on Retroviruses and 
Opportunistic infections, the International Workshop on clinical Pharmacology of HIV Therapy, the 
International AIDS conference and the International Aids Society Conference from 2009 to 2012, to 
identify any studies which may not have been published yet.  I also reviewed all the studies 
referenced by the Liverpool Pharmacology Department Drug interaction information charts for the 
interaction between nevirapine and rifampicin, and nevirapine and isoniazid, to look for any 
additional studies missed by the above search [18]. I included the most recently updated version of 
the FDA approved package insert for Viramune® as a reference for premarketing studies of 
nevirapine metabolism[19]. I also reviewed references of articles that met inclusion criteria to look 
for any additional studies meeting inclusion criteria. 
Data collection 
I screened all retrieved abstracts identified by the search strategy, using the inclusion criteria 
outlined above. I then extracted the data from the studies meeting inclusion criteria, using a data 
extraction form.  
Assessment of study quality 
The Federal Drug Administration  (FDA) in the United States and the European Medicines Agency 
(EMA) have guidelines for drug interaction studies for the pharmaceutical industry, for product 
registration and labelling purposes [20, 21].  However, I could find no formal, validated tool for 
assessing the quality of drug interaction studies. For purposes of assessing the quality of drug 
interactions studies included in this review, I developed a list of 9 criteria for assessment of study 
quality. These are in part derived from the FDA and EMA guidance documents and commentary on 
the FDA guidance [20-23] .  
These criteria aim to address the following questions: 
• Is the study adequately powered to detect an interaction? A power calculation, and 
assumptions made for that calculation, should be documented in the research report. 
 
• Does the design allow the study to characterise the magnitude of the drug interaction that is 
likely to occur when the drugs hypothesised to be interacting are used concomitantly in 
patient management?   
o The ideal study design to allow this may differ depending on the specific interaction 
being studied, and how the drugs under study are used clinically.  In this particular 
case, rifampicin in usually administered to HIV infected patients together with 
isoniazid, as part of a TB treatment regimen, rather than as monotherapy. 
Nevirapine, rifampicin, and isoniazid are generally administered to patients for long 
periods of time, rather than as single doses or short courses of therapy. The extent 
of induction or inhibition observed may be concentration dependent [8, 24]. 
Induction of CYP isoenzymes occurs over days.  At least 7- 14 days of daily rifampicin 
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administration are required to approach maximal induction [7, 25].  In addition both 
nevirapine and rifampicin undergo auto-induction, and rifampicin may take up to 40 
days to reach the fully auto-induced state [19, 25, 26]. Induction by rifampicin takes 
7-14 days to wane [7]. In contrast to induction, inhibition may occur more quickly, 
and wane more quickly [27]. The extent of an inhibitory drug interaction observed is 
therefore likely to be influenced by the timing of administration of the drugs being 
studied. Reporting of dosing times is therefore important. 
o Therefore, to investigate this study question, ideally both rifampicin and isoniazid 
should be administered, doses used in clinical practice should be administered, 
steady state and full induction must have been reached, and auto-induction must 
have occurred, and induction should have waned completely before repeating 
pharmacokinetic sampling without co-administered TB treatment. Dosing times in 
relation to pharmacokinetic sampling of all potentially interacting drugs should be 
reported 
 
• Does the study design minimise important biases, and deal with important confounders? 
o Weight is likely to influence nevirapine concentrations. Changes in weight (in studies 
with repeated pharmacokinetic sampling separated by a month or more) and 
differences in weight (in studies with between group comparisons of 
pharmacokinetic parameters) should therefore be reported and taken into account 
in the analysis.  (This potentially confounding effect may be dealt with by cross-over 
designs with randomised sequence, but this is not possible in studies in patients due 
to treatment requirements.) 
o Both HIV and TB disease states may alter drug absorption and pharmacokinetics, 
and therefore, while healthy volunteer data may be of some use, studies in patients 
with the diseases being treated are important to characterise the extent of any drug 
interaction and its likely impact on treatment efficacy.  
o To minimise confounding and potential bias due to between-participant differences,  
a fixed sequence one way crossover or randomised crossover  design (allowing for 
within-participant comparisons of pharmacokinetic parameters) is a stronger study 
design tha  parallel group designs (with between participant comparisons).  
 
• Is the pharmacokinetic data summarised in a way that captures both the midpoint and the 
variability in the data?  Have investigators defined a threshold for concluding that the 
interaction is clinically significant, rather than merely a statistically significant? 
o The FDA and EMA recommend that changes in the key pharmacokinetic parameters 
should be presented using geometric means and geometric mean ratios and 90% 
confidence intervals [20, 21].  
o The FDA recommends that a  pre-specified equivalence or “no effect” interval 
should be stated, outside of which the interaction is regarded as clinically significant 
[20]. Defining such a boundary for this particular interaction question is difficult. The 
clinical relevance of this interaction is determined by its impact on treatment 
efficacy and/or safety, rather than merely the magnitude of the proportional change 
in pharmacokinetic parameters. The magnitude of change that is significant may 
differ between populations, as nevirapine pharmacokinetic parameters differ 
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between populations [28]. There is a defined target nevirapine Cmin  that is supported 
by efficacy data [15],  which might be used to calculate a population-specific margin 
for proportional change in Cmin, but no defined target AUC . I have therefore not 
included this point as a criterion for appraising quality of studies included in this 
review. 
The criteria that I have used to appraise quality of studies included in this review are as follows. They 
are criteria specific to this interaction question.  
1. Was the study conducted in HIV and TB co-infected participants? 
2. Is a sample size calculation presented? 
3. Is change in weight (for within-participant comparisons with repeated pharmacokinetic 
sampling more than a month apart), or difference in weight (for between group 
comparisons) reported? 
4. Is rifampicin-based TB treatment, including both rifampicin and isoniazid, administered? 
5. Were the doses used in the study the same as those used in clinical practice? 
6. Was pharmacokinetic sampling performed after at least 14 days of nevirapine at full dose, or 
14 days of nevirapine in combination with rifampicin-based TB treatment at full dose? For 
studies with repeated pharmacokinetic sampling, was the second sampling occasion at least 
14 days after adding or removing rifampicin?   
7. Was the timing of administration of all potentially interacting drugs being studied reported- 
i.e. nevirapine, rifampicin and isoniazid? 
8. Does the study design include a within-participant comparison of pharmacokinetic 
parameters?  
9. Are changes in pharmacokinetic parameters (AUC, Cmax and Cmin) presented as geometric 
mean ratios with 90% CI? 
I reviewed all interaction studies using these questions, and recorded the answer as “yes”, “no, 
“unclear” or “not applicable”.  
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Results 
I performed the Pubmed Search on 14 December 2012 and retrieved 608 abstracts (figure 1). I 
identified 11 further records through the additional sources outlined above. I screened 619 records, 
and excluded 587 which did not meet inclusion criteria on review of the abstract. I reviewed 32 
records for eligibility. 7 were excluded; reasons outlined in figure 1. There are 25 records included in 
the results below; 5 exploring metabolism of nevirapine, and 20 exploring the interaction between 
nevirapine and rifampicin or rifampicin-based TB treatment. 
 
Figure 1 Flow diagram of study selection 
  
Records identified through Pubmed search  
(n = 608) 
Records identified through additional sources 
(conference proceedings, revie  of references, Liverpool TDM HIV 
drug interactions references, nevirapine package insert) 
(n = 11) 
Records screened  
(n = 619) 
Records excluded  
(n =587) 
Full-text articles and additional 
records assessed for eligibility  
(n =32) 
Excluded (n=7):  
• No comparator without  
RMP or RMP-based TBT (n = 
4) 
• Only RMP concentrations 
measured, not NVP (n=1) 
• Duplicate- presented at 2 
meetings (n=1) 
• Duplicate- subsequently 
published (n=1) 
 
Included in literature review results (n= 25) 
 
Interaction between NVP and RMP or RMP-based TBT (n=20) 
• Published articles (n =14 ) 
• Conference abstracts (n=6) 
 
NVP metabolism (n=5) 
• Published articles (n=2) 
• Conference abstracts (n=2) 
• Package insert (n=1) 
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Nevirapine metabolism 
I identified four studies [6, 29-31], two of which were only available in abstract form [30, 31]. In 
addition, I reviewed the information from premarketing studies presented in the FDA approved 
package insert [19]. 
An in vitro study performed in human hepatic microsomes showed that nevirapine is metabolised by 
cytochrome P450 isoenzymes to form 2-, 3-, 8- and 12- hydroxynevirapine, predominantly via 
CYP3A4 and CYP2B6 [6]. The metabolite 2- hydroxynevirapine is formed exclusively by CYP3A4 and 
3- hydroxynevirapine exclusively by CYP2B6. The metabolites 8- and 12-hydroxynevirapine are 
formed predominantly by CYP3A4, but other CYP450 isoenzymes (CYP2B6 and CYP2D6 for 8-
hydroxynevirapine, and CYP2D6 and CYP2C9 for 12-hydroxynevirapine) also play a role [6].   
Nevirapine was shown in vitro and in phase 1 studies to induce CYP2B6 and 3A [19]. It therefore 
auto-induces its own metabolism, resulting in a 1.5 to 2 fold increase in  apparent oral clearance, 
and a decrease in half life from 45 hours in single dose studies to 25 to 30 hours following multiple 
dosing [19, 29].   
A healthy volunteer study was conducted in 8 adult men, dosed with nevirapine 200 mg daily for 2 
weeks, increased to 200 mg 12 hourly for a further 2 weeks, then administered a radioactively-
labelled nevirapine dose [29]. Nevirapine was found to be excreted in the urine predominantly as 
glucuronidated conjugates of 2-, 3-, 8- and 12-hydroxynevirapine.  
A pharmacokinetic study (presented at IAS in 2009 and as yet unpublished) of nevirapine and its 
metabolites in 10 African American healthy volunteers sampled for 13 days after a single 200 mg 
nevirapine dose confirmed that 12-hydroxynevirapine was the main metabolite, with 2- and 3- 
hydroxynevirapine as well as 4- carboxynevirapine also detected, but no 8- hydroxynevirapine [30]. 
There was considerable variability in nevirapine clearance, area under the curve (AUC) and half life 
(T1/2) of nevirapine metabolites [30]. The authors speculated that this variability may be due to 
genetic polymorphisms of the CYP isoenzymes responsible for nevirapine metabolism [30].  
A further analysis by this group, presented at CROI in 2012, compared nevirapine metabolite profiles 
from the above single dose study with metabolite concentrations at steady state in 10 HIV-infected 
Cambodians on nevirapine-based ART, (duration  of treatment unspecified in the abstract).  There 
was a marked decrease in the metabolic index (ratio of metabolite to nevirapine area under the 
curve (AUC)) of 2-hydroxynevirapine when comparing single dose to steady state, from a median of 
0.25 (IQR 0.12, 0.66) to 0.04 (IQR 0.03, 0.05).  As 2-hydroxynevirapine is produced exclusively by 
CYP3A4, this finding suggests that CYP3A4 is being inhibited by nevirapine at steady state in this 
study population. The metabolic index for 3-hydroxynevirapine doubled, in keeping with induction of 
CYP2B6. These investigators did not find a significant change in the metabolic index for 12-
hydroxynevirapine, which is produced by CYP3A4, CYP2D6 (considered to be uninducible) and 
CYP2C9, as discussed above. This suggests that nevirapine auto-induction primarily affects CYP2B6 
[31].  
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Effect of rifampicin or rifampicin-based TB treatment on nevirapine pharmacokinetics 
I identified 20 studies, of which 6 were only available in abstract form from conference proceedings 
[13, 32-50]. Characteristics, methods and major findings of the 20 studies are summarised in Table 1-
4.  Three studies explored the interaction between nevirapine and rifampicin; table 1 [32-34]. In one 
study, the majority of participants on rifampicin-based TB treatment [41], and in the remaining 16 
studies the comparison was nevirapine with and without rifampicin-based TB treatment [13, 35-40, 
42, 43, 45-50].   
The study findings as well as weaknesses and strengths are discussed in more detail below. The 
studies are presented in order of publication/conference presentation under each sub-heading. 
Studies exploring the pharmacokinetic interaction between nevirapine with rifampicin 
(Table 1) 
An unpublished study presented at the International AIDS conference in 1998 (with the primary aim 
of characterising the effect of nevirapine on rifampicin concentrations) compared nevirapine 
concentrations in 22 HIV infected individuals on nevirapine to historical controls (number 
unspecified) [32]. Participants were started on rifampicin 600 mg daily, and then received nevirapine 
for 28 days (200mg daily lead in for 14 days, then 200 mg 12 hourly) before pharmacokinetic 
sampling for nevirapine concentrations. Nevirapine Cmin was 68% lower in the presence of rifampicin. 
Rifampicin peak concentration (Cmax) and area under the curve (AUC) were not affected by 
nevirapine. This is a weak study design to explore the effect of rifampicin on nevirapine 
pharmacokinetics.  Results are likely to be confounded by other covariates, and the study has never 
been published or subjected to peer review. 
Thirteen HIV-infected Indian participants on nevirapine-based ART for more than a month were 
intensively sampled before commencing rifampicin 450-600 mg daily, and again one week after [33].  
In the presence of rifampicin nevirapine median Cmin decreased by 53%, with a 46% decrease in 
median AUC. Nevirapine Cmin was sub-therapeutic (<3mg/L) in 8 patients, and daily dose of 
nevirapine was increased by 50% to 300 mg 12 hourly in 7 of these participants, resulting in 
therapeutic concentrations in all 7.  
Twelve Indian healthy male volunteers were administered a single dose of nevirapine, and intensive 
PK sampling up to 336 hours was performed [34]. They were then administered 7 days of rifampicin, 
and intensive sampling was repeated after a second nevirapine dose. There was a 79% decrease in 
AUC0-t and a 60% decrease in concentration at 24 hours (C24) in the presence of rifampicin. This is a 
single dose study, and may not reflect the extent of the interaction once nevirapine auto-induction 
has taken place. 
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Table 1:  Studies exploring pharmacokinetic interaction between nevirapine (NVP) and rifampicin (RMP)  
First author 
(publication 
date) site 
Number of 
participants 
Study population Weight kg 
Mean  ±SD or median 
(IQR) 
 RMP dose Study design Change/difference in NVP PK parameters 
Robinson 
(abstract 1998, 
unpublished) 
22 on NVP –ART 
Number of controls 
not given 
HIV-infected  
Historical controls 
(no details given) 
not specified  600 mg daily RMP for 14 days 
RMP + NVP-ART for 28 days 
Intensive PK sampling day 14 (RMP) and 42 (RMP + 
NVP). Sampling schedule not stated. 
Cmin 68 % ↓ in the presence of RMP. 
No significant change in RMP Cmax and AUC  with NVP 
 
Ramachandran 
(2006) 
 India 
13  HIV-infected on 
NVP-based ART 
mean (range): 58 (38, 91)  450-600 mg 
daily 
Sampled before commencing RMP and again after  
7 days of RMP 
Intensive sampling 0.5, 1, 1.5, 2, 4, 6, 12 hrs after 
dosing. Within-participant comparison. 
Dose of NVP ↑ 50%   if Cmin < 3 mg/L, and 1 and 12 
hr conc day 0 and day 7 of RMP 
Mean Cmax: 42%  ↓* 
Median Cmin:  53% ↓* 
Median AUC: 46% ↓* 
Cmin  mean ±SD mg/L on standard dose NVP:  
2.6 ±1.4 with RMP, 5.5 ± 2.4 without RMP 
Cmin>3 mg/L in 7/7 with NVP dose ↑ 
Pujari 
(abstract 2006, 
unpublished) 
India 
12 Healthy volunteers median  51, no range given  450-600 mg 
daily 
Single dose of nevirapine 
Intensive sampling 0.5, 1, 1.5, 2, 4, 6, 12, 24, 48, 
72, 336 hrs after dosing. 
7 days of RMP. Intensive sampling then repeated. 
Mean Cmax: 20%  ↓ (p=0.13)  
Mean C24:  60% ↓* 
Mean AUC: 79% ↓* 
 
*p value<0.05 
Abbreviations: conc  concentration, DOT directly observed therapy, GMR geometric mean ratio, IQR interquartile range,  NVP-ART nevirapine –based antiretroviral therapy, RMP – rifampicin, 
RMP-TBT  rifampicin-based TB treatment , SD standard deviation, TB  tuberculosis, TBT  TB treatment ,Cmin  trough concentration 
 
  
1
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Studies with intensive sampling exploring the pharmacokinetic interaction between 
nevirapine and rifampicin-based TB treatment (Table 2) 
Ribera et al conducted a small pharmacokinetic study in HIV and TB co-infected patients in Spain, 
published in 2001 [35]. Five patients taking ART including nevirapine 200mg 12 hourly (duration of 
ART not stated) had intensive sampling performed before initiating rifampicin-based TB treatment, 
and again 12 or more days after TB treatment initiation. Results of this study suggested that 
concomitant rifampicin-based TB treatment increased nevirapine elimination and decreased 
nevirapine exposure. There was a 42% decrease in the median AUC in the presence of rifampicin-
based TB treatment. The study was underpowered, and although the median Cmin decreased by 20%, 
the change was not statistically significant. Of note, all 5 participants had a Cmin of less than 3mg/L 
(range 1.1-2.8 mg/L) in the presence of rifampicin-based TB treatment, and 4/5 had concentrations 
below 3 mg/L before TB treatment.  These low concentrations in a small sample may be due to 
chance, or reflect poor adherence. This study also included a comparison of rifampicin 
pharmacokinetic parameters between this group and 5 participants on rifampicin-based TB 
treatment only, and found no significant differences. 
We performed intensive pharmacokinetic sampling in 16 South African HIV and TB co-infected 
participants concomitantly treated with nevirapine-based ART and rifampicin-based TB treatment 
[13]. Participants were sampled during the continuation phase of TB treatment, and after TB 
treatment completion.  We found that rifampicin-based TB treatment significantly decreased 
nevirapine plasma concentrations in South African participants. The extent of reduction in Cmin 
varied between participants, with a mean decrease in Cmin of 26% (95% CI 6, 46). Nevirapine 
concentrations were sub-therapeutic (<3mg/L) in 6/16 participants during TB treatment, and none 
after TB treatment completion. The ratio of nevirapine AUC to 12-hydroxynevirapine AUC was 
significantly lower in the presence of TB treatment, consistent with induction of nevirapine 
metabolism. Half of participants had a rifampicin Cmax lower than the recommended reference range 
[51], in keeping with other data in South African HIV and TB co-infected patients [52]. 
After our study was published, 4 further intensive pharmacokinetic studies in African patients were 
presented. 
Matteelli et al conducted a study in 16 HIV and TB co-infected patients in Burkino Faso [36]. 
Participants were on rifampicin-based TB treatment, and pharmacokinetic sampling was performed 
4 and 12 weeks after NVP-based ART initiation and again 4 weeks after TB treatment completion. 
Nevirapine concentrations at 4 weeks of ART were similar to those seen in our study, Cmin median 
(range) 3.8 (0.9, 9.8) mg/L and AUC(0–12)  median (range) 43.7 (19.6, 134.2)mg/h/L. The Cmin geometric 
mean ratio comparing week 4 to post TB treatment was 0.67 (90% CI 0.64, 0.90). However, the 
difference between pharmacokinetic parameters was less when comparing week 12 to post TB 
treatment values (see table 2 for details).These investigators suggest that rifampicin induction may 
wane over time, causing nevirapine concentrations to increase from 4 and 12 weeks in their study 
participants. However this hypothesis is at odds with our study findings- we sampled patients later in 
TB treatment than in this study, during the continuation phase of TB treatment and found a bigger 
difference in nevirapine Cmin  with and without TB treatment than their week 12 results suggest. The 
investigators also suggest that nevirapine concentrations increased with improved absorption and 
recovery. However, this does not explain why the differences they found comparing week 12 to post 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
14 
 
TB treatment are less than those observed in our study, as our participants would already have 
recovered with any attendant improvement in absorption.  Participants in Matteelli et al’s study had 
advanced disease and 4 of the 16 died. (Two participants died during TB treatment, one before 12 
weeks. Two died after TB treatment completion, one of them before the post-TB sampling occasion.) 
The number of participants included in each comparison is not stated in the paper. The statistical 
methods used were for paired samples, therefore participants with data available at only one time 
point could not have been included the comparisons, and should not have been included in the 
estimates at each time point.  It is possible that the difference between 4 and 12 week 
concentrations is in part due to participant attrition (at least 1 participant had died before the 12 
week time point, and a further 1 or 2 before the post TB time point).  
A pharmacokinetic substudy of the CARINEMO RCT intensively sampled 20 Mozambican participants 
(taking rifampicin based TB treatment and initiated on nevirapine 200 mg with no lead-in dosing) at 
2 and 4 weeks after ART initiation, and 16/20 participants a month after TB treatment completion 
[37]. This study found that 19/20 had nevirapine Cmin > 3 mg/L at 2 weeks, and all were therapeutic 
at 4 weeks. Mean ± SD Cmin concentration was 4.9 ± 1.8 mg/L with TB treatment and 5.7 ± 1.8 mg/L 
without TB treatment; a 14% decrease. Of interest, Cmin concentrations were higher than those 
found in our study. This difference may be due to chance or the fact that our participants had higher 
body weight with mean weight of 66 ± 17 kg in our study versus a median of 53 kg (IQR 48, 56) in the 
Mozambican study. 
In Malawi, nevirapine concentrations were measured in 20 patients stable on nevirapine-based ART 
before and 14 days after initiation on rifampicin-based TB treatment [38]. There was a 22% decrease 
in geometric mean AUC in the presence of TB treatment, and 6/20 (30%) had sub-therapeutic 
nevirapine Cmin on rifampicin-based TB treatment.  
Villani et al conducted a further study in Burkino Faso (the title in the abstract book specifying South 
African participants is an error) in 20 HIV-1 and TB co-infected participants on rifampicin-based TB 
treatment initiated on nevirapine-containing ART [39]. A similar study design to Mattelli et al was 
used, with intensive sampling at week 4 and 16 after initiation of nevirapine-based ART and again 4 
weeks after TB treatment completion. In contrast to this group’s previous study [36] Cmin and AUC 
were similar at week 16 and week 4 (see table 2 for details), refuting this group’s hypothesis 
regarding waning of rifampicin induction. In this study 15% of participants at 4 weeks and 35% at 16 
weeks had Cmin<3 mg/L, with none sub-therapeutic after TB treatment completion. Rifampicin 
concentrations were measured at week 4 and 16, and were similar at both time points. Median 
rifampicin Cmax was 4.1 mg/L (IQR 1.3, 5.4) at 4 weeks, and 2.3 mg/L (IQR 1.5, 4.3) at week 16. These 
rifampicin concentrations are lower than those found in our study, and decrease between time 
points. This may be due to poor adherence, rifampicin auto-induction (which may not have been 
maximal at the first sampling point) or failure to adjust rifampicin doses as participants recovered 
and gained weight. 
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Table 2:  Studies with intensive sampling exploring the pharmacokinetic interaction between nevirapine (NVP) and rifampicin-based TB treatment (RMP TBT)  
First author  
(pub date)  
 site 
Number of 
participants 
Study population Weight kg mean 
±SD / median (IQR) 
RMP dose Study design Sampling 
schedule 
Change/difference in NVP PK parameters 
Ribera* (2001) 
Spain 
10  
(5 on NVP) 
HIV + TB co-infected.  
5 on NVP-ART; initiated 
on RMP- TBT. 
5  initated on RMP-TBT 
only 
not specified 600 mg daily Sampled before commencing TB treatment 
and after 12 or more days of TB treatment 
Within-participant comparison NVP  
Between group comparison of RMP 
0.5, 1, 1.5, 2, 4, 
6, 12 hrs after 
NVP dose 
Median Cmax: 19%  ↓** 
Median Cmin:  20% ↓ 
Median AUC: 42% ↓** 
Cmin median (range) mg/L: 1.8  (1.1, 2.8)  with TBT, 
2.3 (1.4, 3.4) without TBT 
Cohen (2008) 
South Africa 
16 HIV + TB co-infected; on 
RMP-TBT and NVP-ART 
RMP-TBT: 66 ±17  
After TBT: 69 ±16 
 450-600 mg daily, 
5 days a week 
Sampled during continuation phase of RMP-
TBT and 10 days or more after TBT 
completion.  
Within-participant comparison 
0.5, 1, 1.5, 2, 4, 
6, 12 hrs after 
NVP dose 
GMR (90% CI)  on/after RMP-TBT 
Cmax:  0.61 (0.49, 0.79) 
Cmin:  0.68 (0.53, 0.86) 
AUC0-12:  0.64 (0.52, 0.80) 
Mean Cmin ↓: 26% (95% CI 6, 46) 
Cmin median (IQR ) mg/L on/after TBT: 
3.2 (2.8, 4.5)/ 4.4 (3.6, 6.9)** 
Matteelli (2009) 
Burkino Faso 
16  HIV + TB-co-infected. On 
RMP-TBT;  initiated on 
NVP-ART 
median 52 (range 
33, 67) 
 450-600 mg daily Intensive PK sampling 4  and 10 weeks after 
NVP initiation and 4 weeks after end of TBT 
Within-participant comparison 
0,  1, 2, 4, 6, 12 
hrs after NVP 
dose 
Cmin median (range) mg/L: 
a) NVP+ TBT 4 weeks 3.3 (0.6, 10.5) 
b) NVP + TBT 12 weeks  3.9 (1.0, 11.0))  
c) NVP 4 weeks post TBT 4.2 (1.5, 8.3) 
a vs b p=0.86; a vs c p=0.01; b vs c p=0.17 
median Cmin 20% ↓; median AUC 26% ↓ (a vs c) 
median Cmin 7% ↓; median AUC 8 % ↓ (b vs c) 
Cmin GMR (a vs c) 0.69 (90% CI 0.58, 0.83)  
AUC GMR (a vs c) 0.73 (90% CI 0.60, 0.88) 
Bonnet 
(abstract 2009, 
unpublished) 
Mozambique 
20  
 
HIV + TB-co-infected.  
On RMP- TBT;  initiated 
on NVP-ART  
53 (48, 56) not stated Cmin 2 weeks after starting TBT 
Intensive sampling 4 weeks after starting 
TBT and 4 weeks after TBT completion 
Within-participant comparison 
0.5, 1, 1.5, 2, 4, 
6, 12 hrs after 
NVP dose 
GMR (90% CI)  without/ with RMP-TBT 
Cmax:  1.13(0.99, 1.28) 
Cmin:  1.14(0.99, 1.31) 
AUC0-12:  1.20(1.02, 1.42) 
Cmin mean ±SD mg/L  on/ after RMP TBT 
 4.9 ±1.8 mg/L /5.7 ±1.8  
AUC12mean  ±SD  h.mg/L on / after TBT 
70.05 ±20.96/ 80.03 ±24.05  
Chaponda  
 (abstract 2010, 
unpublished) 
Malawi 
20 on NVP-
ART initiated 
on RMP-
based TBT 
HIV + TB-co-infected. On 
NVP-ART; initiated on 
RMP-TBT. 
Not stated not stated Intensive sampling before initiating TBT and 
after 14 days. Cmin only day 3 and 7 
Within-participant comparison 
0, 1, 2, 4, 8 hrs 
after NVP dose 
 Cmin only day 3 
and 7 
22% ↓in geometric mean AUC 
 
Villani (2012) 
Burkino Faso 
20  HIV and TB-co-infected Not stated  not stated Intensive PK sampling 4  and 16 weeks after 
NVP initiation and 4 weeks after end of TBT 
Within-participant comparison 
0, 1, 2, 4, 6, 12 
hrs after NVP 
dose 
Cmin median (IQR) 4 wks/16 wks/post TBT mg/L  
4.6  (3.2, 5.9) /3.5  (2.4, 5.1) /6.5  (4.1, 9.5) 
AUC median (IQR) 4 wks/16 wks/post TBT mg.h/L 
65.8 (52.5, 94.9)/ 53.6 (39.5, 75.3) 91.2 (67.9,112.0) 
* Changes in median PK parameters have been recalculated from values quoted in the paper;  values for percentage change in the median in the paper are incorrect 
**p value<0.05 
Abbreviations:  CI confidence interval, Cmax peak concentration, Cmin  trough concentration, IQR interquartile range,  GM geometric mean, GMR geometric mean ratio, NVP-ART nevirapine –
based antiretroviral therapy, RMP – rifampicin, RMP-TBT  rifampicin-based TB treatment , SD standard deviation, TB  tuberculosis, TBT  TB treatment 
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Studies with sparse sampling exploring the pharmacokinetic interaction between nevirapine 
and rifampicin-based TB treatment (Table 3) 
A small study conducted in London in 1999 compared nevirapine Cmin concentration in 7 co-infected 
patients on rifampicin-based TB treatment, dosed twice weekly, with 13 controls not on TB treatment 
[40]. This study found that TB treatment had little effect on nevirapine concentrations, with a non-
significant 8% decrease in Cmin. Mean ±SD Cmin in participants on TB treatment was 4.3 ±1.5 mg/L. 
Auter et al analysed nevirapine TDM requests in Thai patients on nevirapine-based ART and compared 
random concentrations in 74 patients taking concomitant rifampicin with 74 controls not taking 
rifampicin [41]. Method of selecting the controls is not described. Isoniazid was recorded as a 
concomitant medicine in 64/74 on rifampicin. Nevirapine Cmin concentrations were 34% lower in the 
presence of rifampicin, with a mean ±SD concentration of 5.3 ±2.7 mg/L in the presence of rifampicin 
compared to 8.0 ±3.3 mg/L without rifampicin (95/128 participants had Cmin concentrations). Trough 
concentrations in both groups are high, with only 9 Cmin concentrations below a TDM target of 3.1mg/L, 
7 of these in the rifampicin group. 
Manosuthi et al compared nevirapine concentrations in two groups of Thai patients, 70 with and 70 
without rifampicin-based TB treatment [43].  The mean nevirapine Cmin concentration was 18% lower in 
the presence of TB treatment. After 8 weeks of ART 30% of participants on TB treatment and 7% of 
participants not on TB treatment had nevirapine concentrations below 3.4 mg/L. In a second 
publication, nevirapine concentrations in the group on rifampicin-based TB treatment were repeated 
after completion of TB treatment, and nevirapine Cmin was 15% lower in the presence of TB treatment 
by this within-participant comparison [42].  
Stöhr et al retrospectively analysed data extracted from the Liverpool TDM registry and UK collaborative 
HIV cohort on 179 patients on nevirapine-based ART [44]. On multivariate analysis they found that black 
race (39% higher), concomitant rifampicin-based TB treatment (40% lower), concomitant tenofovir (22% 
higher), and concomitant protease inhibitor (28% higher) were independent predictors of nevirapine 
concentrations  
Uttayamakul et al measured nevirapine Cmin concentrations in 59 Thai HIV and TB co-infected patients 
on rifampicin-based TB treatment at 6 and 12 weeks after ART initiation and 1 month after TB 
treatment completion [45]. Participants were genotyped for CYP2B6 and CYP3A4 polymorphisms. The 
CYP2B6 516G>T polymorphism had a T allele frequency of 30%, but only 2 (4%) were TT homozygotes 
(see table 3 for details of genotype frequency). The genotype distribution in this patient group is not in 
Hardy Weinberg equilibrium (calculated from genotype frequency, Chi squared= 3.96, p=0.047). This is 
not addressed by the authors, and may indicate a problem with the genotyping technique. These 
investigators found similar nevirapine concentrations on and off rifampicin-based TB treatment to those 
previously observed in Thai patients, with a 16% decrease due to rifampicin based TB treatment. The 
analysis by CYP2B6 516G>T was underpowered, and it is difficult to work out from the text which 
comparisons found significant differences, but concentrations of nevirapine were highest at all time 
points in the TT group (see table 3 for details). Data in this paper suggest that CYP2B6 516G>T genotype 
is an important determinant of nevirapine concentrations, and impaired CYP2B6 function in those with 
the T allele results in decreased nevirapine elimination even in the presence of rifampicin-based TB 
treatment. It is interesting to note that nevirapine concentrations in the TT homozygote group were 
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higher on rifampicin-based TB treatment at the first time point on rifampicin-based TB treatment than 
they were after TB treatment completion, although this study is underpowered to reach definitive 
conclusions, with only 2 TT homozygotes in the nevirapine group.  
Sinha compared nevirapine Cmin concentrations in 63 participants on nevirapine-based ART and 
rifampicin based TB treatment, with concentrations in 51 participants on nevirapine-based ART 
alone[46].  Concentrations were lower with TB treatment (although not significantly so; probably 
because the study was underpowered). 
A cross sectional study of random nevirapine concentrations in 40 Indonesian patients on nevirapine-
based ART, 16 of them on rifampicin based TB treatment, found that mean random concentration was 
27% lower in the presence of rifampicin. Dose to sampling time is not stated. 1/24 participants had Cmin 
< 3 mg/L on TB treatment[47]. 
Population pharmacokinetic analyses exploring the interaction between nevirapine and 
rifampicin-based TB treatment (Table 4) 
A non linear mixed effects model, which included the data in our analysis, as well as additional intensive 
and sparse pharmacokinetic data from participants in Cape Town, was constructed by Elsherbiny et al. 
In this model, rifampicin-based TB treatment increased nevirapine clearance by 37% [48]. Elsherbiny et 
al simulated nevirapine plasma concentration profiles at nevirapine doses of 300 mg, 400 mg and 500 
mg. These simulations suggested that a dose of 300 mg 12 hourly would result in Cmin concentrations 
above 3mg/L in most patients from this population.   
A second non linear mixed effects model constructed by Svensson et al, included our data, together 
with data from 2 additional data sets[50]. This analysis suggested that the predominant effect of 
rifampicin-based TB treatment was in decreased nevirapine bioavailability rather than increased 
clearance. This is a surprising finding, as nevirapine has low extraction due to metabolism at gut level, 
with bioavailability of 90% after single dose[19] and is a weak substrate of P-glycoprotein (which is 
induced by rifampicin)[50].The authors suggest nevirapine auto-induction may decrease bioavailability, 
so that rifampicin’s effect on gut metabolism may be more marked than is expected from single dose 
studies. This requires further research. Seventeen percent of individuals in the model had reduced 
nevirapine clearance. Study participants were not genotyped, but it is possible that those with reduced 
clearance are TT homozygotes for the CYP2B6 516G>T polymorphism, with impaired CYP2B6 function. 
The prevalence of lower clearance is in keeping with the prevalence of this polymorphism previously 
found in the South African population[5]. 
An unpublished population pharmacokinetic analysis was conducted using intensively sampled data 
from 24 participants in Burkino Faso on rifampicin-based TB treatment initiated on nevirapine-based 
ART[49]. Participants were sampled 1 and 2 months after nevirapine initiation, and 1 and 6 months after 
TB treatment completion. These investigators found a 21% decrease in nevirapine clearance after 
stopping TB treatment. The change in clearance ranged between 0 and 44%, with 30% of participants 
having no change in clearance. The authors suggest that this variability may be due to CYP2B6 genetic 
polymorphisms. 
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Table 3: Studies with sparse sampling exploring the pharmacokinetic interaction between nevirapine (NVP) and rifampicin-based TB treatment (RMP TBT) 
First author 
(publication 
date) site 
Number of 
participants 
Study population Weight kg 
Mean ±SD or median 
(IQR) 
 RMP dose Study design Change/difference in NVP PK parameters 
Dean (1999) 
London 
7 on NVP-ART and 
RMP-based TBT 
13  on NVP + 
nelfinavir + 2 NRTIs  
HIV + TB co-infected 
Comparator group 
are HIV-infected 
not specified  600 mg twice 
weekly 
  Between group comparison of Cmin  
 
Mean Cmin.   ↓ 8%  (p=0.54) 
Autar (2005) 
Thailand 
74 on RMP + NVP- 
ART 
 74 on  NVP- ART 
HIV-infected  
Indication for RMP 
not described.  
RMP: 54 (49,61)  
Controls: 58 (51, 63)   
64/74 on RMP 
and isoniazid. 
(450-600 mg 
daily) 
Analysis of results of NVP TDM requests. Single 
samples at random time-points within dosing 
interval. 
50/ 74  Cmin on RMP, 45/74 Cmin  in control group 
Mean Cmin  ↓ 34%* 
Cmin  mean ±SD mg/L:  
5.3  ±2.7 with RMP, 8.0 ±3.3 without RMP 
Manosuthi 
(2006) 
Thailand 
70 on RMP- TBT +  
NVP–ART  
70 on  NVP– ART 
HIV + TB co-infected  
Comparator group 
are HIV infected 
Mean 54. No SD given. RMP-based TBT  
(450-600 mg 
daily) 
Cmin 12 hrs after DOT at 8 and 12 weeks after 
initiation of ART 
Between group comparison 
Mean Cmin ↓18%   * 
Cmin  mean ±SD mg/L:  
5.4 ±3.5 with RMP, 6.6 ±3.1 without RMP 
Manosuthi 
(2007) 
Thailand 
70 on RMP- TBT +  
NVP–ART  
 
HIV + TB co-infected  
Comparator group  
HIV infected 
TB: 55 ±9 
Controls: 54 ±10 
RMP-based TBT 
(450-600 mg 
daily) 
Within-participant comparison of Cmin 12 hrs after 
DOT at 8 and 12 weeks and Cmin after completion 
of TBT (interval from  end of TBT to sampling not 
stated) 
Mean Cmin ↓15%  * 
Cmin  mean ±SD mg/L:  
5.4  ±3.5 with TBT, 6.4 ±3.4 without TBT 
Stohr  (2008) 
London 
10 on NVP-ART and 
RMP-based TBT 
169  on NVP-ART 
HIV + TB co-infected  
Comparator group  
HIV infected 
71 (65, 78) Not stated  Retrospective analysis of results of NVP TDM 
requests 
NVP conc predictors: black race (39% ↑ ),  concomitant 
rifampicin (40%  ↓), concomitant tenofovir (22% ↑), 
concomitant protease inhibitor (28% ↑)   
Uttayamakul 
(2010) 
Thailand 
59 on RMP-TBT 
initiated on NVP-
ART 
GG: 26 (44%) GT: 31 
( 53%) TT 2( 3%) 
HIV + TB-co-infected 54  ±9  RMP-based TBT 
(450-600 mg 
daily) 
Between participant comparison, by 
CYP2B6 516G>T genotype.   Within participant 
comparison on and off TBT 
Cmin measured at week 6 and 12 of ART and 
1month after TBT completion 
Cmin mean ±SD wk6 / wk 12/after TBT mg/L 
GG 5.4 ±0.5/ 5.3 ±0.5/ 6.4 ±0.6 
GT 5.7 ±0.5/ 5.6 ±0.5/7.03 ±0.6 
TT 14 ±9.5/ 7.9 ±2.8/ 9.4 ±0.2 
Whole group 5.8 ±4/5.7 ±2.6/ 6.8 ±3.4* 
NVP 16% ↓ with RMP-based TBT 
Sinha (2011) 
India  
63 on RMP- TBT +  
NVP–ART  
51 on  NVP–ART 
HIV + TB-co-infected TB group 48 ±8  
Comparator group 51 ±10 
Not stated Cmin measured in the morning at 2 weeks, 4 weeks, 
42 days and 6 months 
Cmin mean ±SD mg/L TBT  vs control group: 
2 wks 2.2 ±1.5 vs. 3.3 ±5.0 (p = 0.10) 
4wks 2.8 ±1.6 vs. 3.7 ±3.6 (p = 0.08) 
42 days 3.1 ±3.3 vs. 4.0 ±2.6 (p = 0.10) 
Nafraidi (2012) 
Indonesia  
16 on RMP- TBT + 
NVP-ART 
24 NVP- ART 
 
HIV + TB-co-infected 
Comparator group 
HIV-infected 
TBT 52 ±9 
 
Comparator group 59 ±9 
RMP-based TBT 
Dose of RMP 
not stated 
Cross sectional study comparing random NVP 
concentrations between the groups. Dose to 
sampling times not given.    
NVP mean ±SD mg/L 
NVP 7.5 ±2.2 ; NVP + TBT 5.5 ±2.7* 
Mean random NVP conc 27% ↓ with TBT 
*p value<0.05 
Abbreviations: DOT directly observed therapy, IQR interquartile range,  NVP-ART nevirapine –based antiretroviral therapy, RMP – rifampicin, RMP-TBT  rifampicin-based TB treatment , SD 
standard deviation, TB  tuberculosis, TBT  TB treatment ,Cmin  trough concentration 
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Table 4:  Population pharmacokinetic analyses exploring the interaction between nevirapine (NVP) and rifampicin-based TB treatment 
First author 
(publication 
date) site 
Number of 
participants 
Study population Weight kg 
Mean (SD) or median 
(IQR) 
RMP/RMP-
based TBT 
(RMP dose) 
Study design Change/difference in NVP PK parameters 
Elsherbiny 
(2008) 
South Africa 
27 on NVP-ART and 
RMP-based TBT 
26  on NVP-ART 
HIV + TB co-infected 
Comparator group 
are HIV-infected 
Median 68 (range 43, 105) RMP-based TBT  
(450-600 mg 
daily) 
Nonlinear mixed effects modelling, including 
intensively and sparsely sampled participants 
Those with TB sampled on and after TBT 
NVP clearance ↑37%  with RMP-based TBT 
Regazzi  
(abstract 2010, 
unpublished) 
Burkino Faso 
24 on RMP- TBT 
initiated on NVP-
ART 
HIV + TB-co-infected Not stated RMP-based TBT  
Dose not stated 
Sampled at 1 month and 2 months after initation 
of NVP, and 1 and 6 months after TBT completion 
Sampled 0,  1, 2, 4, 6, 12 hrs after NVP dosing 
Population pharmacokinetic analysis performed 
using  P-PHARM software 
21% ↓in nevirapine clearance without RMP-based TBT 
Svennson 
(2012) 
South African 
27 on NVP-ART and 
RMP-based TBT 
88  on NVP-ART 
HIV + TB co-infected 
Comparator group 
are HIV-infected 
TBT median 67 (range 43-
102) 
RMP-based TBT  
(450-600 mg 
daily) 
Nonlinear mixed effects modelling, including 
intensively and sparsely sampled participants 
Those with TB sampled on and after TBT 
Data from 3 studies included in the model 
NVP bioavailability ↓ 61% by RMP=based TBT  
17%  of study population have reduced nevirapine 
clearance 
Abbreviations: IQR interquartile range, NVP-ART nevirapine –based ART, RMP – rifampicin, RMP-TBT rifampicin-based TB treatment, SD standard deviation, TB tuberculosis, TBT TB treatment  
 
             Table 5: Assessment of study quality 
First author  
(date if > 1 study) 
HIV and TB 
co-
infected? 
Sample size 
calculation? 
Weight change/ 
difference 
between groups 
reported? 
Rifampicin and 
isoniazid 
administered? 
Doses used in 
clinical 
practice? 
14 days of 
administration 
before each PK 
sampling? 
Timing of drug 
administration 
reported for all 
relevant drugs? 
Within 
participant 
comparison 
Geometric 
mean and 90% 
CI? 
Robinson  U N N N Y  Y N N N 
Ramachandran Y N NA N Y  N Y Y N 
Pujari N N N N N  N N Y N 
Ribera Y N NA Y Y ( I) N N Y N 
Cohen Y Y Y Y Y ( I) N Y Y Y 
Matteelli Y N N Y Y (I) Y N Y Y 
Bonnet Y N N Y U Y N Y Y 
Chaponda Y N N Y U Y N Y N 
Villani Y N N Y U Y N Y N 
Dean Y N N Y N U N N N 
Autar Y N Y Y Y (I) U N N N 
Manosuthi (2006) Y Y Y Y Y (I) Y N N N 
Manosuthi (2007) Y N N Y Y (I) U N Y N 
Stohr  Y N N Y U U N N N 
Uttayamakul Y N N Y Y (I) Y N Y N 
Sinha Y N Y Y U Y N N N 
Nafrialdi Y Y Y Y U U N N N 
Elsherbini Y NA N Y U N U Y NA 
Regazzi Y NA NA Y U Y U Y NA 
Svennson Y NA NA Y U N N Y NA 
Abbreviations: I dose of isoniazid not reported, NA not applicable, N no, Y yes, U unclear 
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Assessment of quality of included studies 
My assessment of the quality of included studies, based on the 10 criteria outlined in the methods 
above, is presented in table 5. The studies appear in table 5 in the same order as in the text and tables 
1-4 above.  
Most studies were conducted in HIV-infected participants. In the majority of studies rifampicin-based TB 
treatment rather than rifampicin alone was studied. Most studies conducted pharmacokinetic sampling 
after 14 or more days of nevirapine, or nevirapine plus rifampicin/rifampicin-based TB treatment 
administration, with the second sampling occasion at least 14 days after adding or removing rifampicin 
rifampicin-based TB treatment.  In the remaining 6 studies, the time interval ranged from 7 to 12 days.   
Only 3/17 studies for which this criterion was relevant presented a sample size calculation.  Only 4 
studies reported on weight changes between sampling occasions, or weight differences between 
groups. Only 2 studies clearly reported the timing of administration of nevirapine as well as rifampicin 
or rifampicin-based TB treatment.  Nine studies reported doses of nevirapine and rifampicin that are 
used in clinical practise, but none of the 17 studies where both rifampicin and isoniazid were 
administered as components of TB treatment reported the isoniazid dose. Only 3/17 for which this 
criterion was relevant presented geometric mean ratios with a 90% confidence interval in the results.  
Summary of findings to date 
Nevirapine concentrations are reduced by concomitant rifampicin, but nevirapine does not affect 
rifampicin concentrations. The reduction in nevirapine concentrations is greater with rifampicin alone 
than when rifampicin is administered in combination with isoniazid as part of a TB treatment regimen. 
Nevirapine Cmin concentrations differ between populations, with Thai and Indonesian patients having 
higher concentrations than African, Indian and Spanish patients, both with and without rifampicin/ 
rifampicin-based TB treatment. Modelling suggests that a 50% dose increase in nevirapine dose when 
administered with rifampicin-based TB treatment may be appropriate in African patients. 
Polymorphisms of CYP isoenzymes, specifically the CYP2B6 516G>T polymorphism, influence nevirapine 
concentrations, and may modify the interaction between nevirapine and rifampicin-based TB 
treatment.  
Gaps in current knowledge and questions for future research 
Differing effects of rifampicin alone, and rifampicin administered with isoniazid 
The first studies exploring co-administration of nevirapine with rifampicin did not distinguish between 
administration of rifampicin alone and co-administration of rifampicin with other drugs used in TB 
treatment, particularly isoniazid. Comparison of study results suggests that this approach was overly 
simplistic.  Results of studies where nevirapine is administered with rifampicin differ from those with 
rifampicin-based TB treatment. Studies with rifampicin alone found a 53-68% decrease in Cmin [32-34], 
and a 46-79% decrease in AUC [33, 34]. In contrast, studies with rifampicin-based TB treatment found 
more modest decreases in nevirapine concentrations, with Cmin decrease ranging from 7  to 34%  [13, 
35-43, 45-50] and decrease in AUC ranging from 22 to 42%[13, 35, 36, 38, 39]. This difference in the 
magnitude of the interaction observed is likely to be due to the presence of isoniazid in TB treatment 
regimens. Isoniazid has been shown in vitro to be a potent mechanism-based inhibitor of CYP3A 
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isoenzymes at concentrations achieved by therapeutic doses [8, 9]. Therefore changes observed in 
nevirapine pharmacokinetics are likely to result from the combined effect of rifampicin, which causes 
gene up-regulation and increased CYP3A expression, and isoniazid, which inhibits functioning of CYP3A.   
The extent of the inhibitory effect of isoniazid is dose dependent, and may therefore vary with 
acetylator status, as slow acetylators have slower isoniazid metabolism and higher isoniazid 
concentrations [8] In addition, other covariates, such as weight, changes in weight in studies with 
within-patient repeated measures, and pharmacogenetic factors are also likely to have bearing on the 
magnitude of changes observed, yet these factors were not always taken into account in analyses to 
date. The possibility that rifampicin auto-induction, (which takes 40 days to reach full auto-induction) 
[25]  also contributes to interactions has also not been taken into account in studies to date.   
 
A South African pharmacokinetic substudy of an isoniazid preventative therapy RCT, including 21 HIV-
infected participants on nevirapine-based ART,  compared nevirapine concentrations between the 8 
participants randomised to isoniazid and the 13 randomised to placebo [53]. In this study median 
nevirapine AUC was 24% higher in the presence of isoniazid (AUC0–12 median (IQR) mg·h/l 62.5 (52.9, 
87.8) without and 77.8 (56.6, 85.5) with isoniazid). Median Cmin was 33% higher in the presence of 
isoniazid (Cmin median (IQR) mg/L 4.5 (3.9, 6.2) without and 5.9 (4.0, 6.5) with isoniazid). The study was 
underpowered, and these differences were not significant (p=0.66 and p=0.61 respectively). An 
adequately powered study is needed to confirm or refute the hypothesis that inhibition of CYP3A4 by 
isoniazid decreases nevirapine metabolism. Ideally this should be demonstrated with a within-
participant, rather than between-participant, comparison of nevirapine pharmacokinetic parameters in 
the presence of isoniazid.  In addition, further studies are required to characterise the effects of 
rifampicin alone compared to rifampicin with isoniazid. This would ideally require a steady state, within 
participant comparison of nevirapine concentrations. Nevirapine concentrations should be compared at 
4 points:  when administered with rifampicin alone, with isoniazid alone, with rifampicin and isoniazid, 
and without either drug.  However, this design poses ethical challenges, as the study would need to be 
conducted in HIV-infected participants, because of safety concerns with repeated dosing of nevirapine 
in healthy volunteers[19]. Rifampicin administered with nevirapine at standard doses without isoniazid 
is likely to cause sub-therapeutic nevirapine concentrations, which may result in resistance and 
compromise future ART options.  
 
Such studies would need to include characterisation of acetylator status of participants, and take into 
account other important covariates such as weight, and genetic polymorphisms affecting nevirapine 
metabolism by CYP450 isoenzymes. 
Optimal dosing of nevirapine with rifampicin-based TB treatment 
The optimal dose of nevirapine when administered with rifampicin-based TB treatment is the most 
important question to inform clinical practice, as nevirapine at standard doses is associated with poorer 
virological outcomes in African patients on rifampicin-based TB treatment [4, 12].  Nevirapine is likely to 
remain part of treatment regimens because of cost constraints and contraindications to efavirenz in 
some patients. The question of optimal dosing of nevirapine with TB treatment in resource-limited 
settings, and particularly in African patients therefore needs to be resolved.   
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Eighteen Ugandan participants on rifampicin-based TB treatment (not included in the literature review 
above as participants were only sampled on rifampicin-based TB treatment, with no comparator group 
off TB treatment) were randomised to 200 mg daily or 200 mg 12 hourly for the first 2 weeks of 
ART[54]. This study confirmed that nevirapine concentrations are sub-therapeutic with once daily lead-
in dosing, with a geometric mean Cmin 1.5 (90% CI 1.1, 2.1) mg/L in the lead-in group. This is in keeping 
with other studies[10, 11], and lead-in nevirapine dosing is no longer recommended with TB 
treatment[1]. However, the question of dosing beyond the lead-in period has not been resolved. The 
Ugandan RCT continued all study participants on nevirapine 200 mg 12 hourly, and found that Cmin 
concentrations were less than 3 mg/L in 64% of participants in this study at day 21, after 7 days of full 
dose nevirapine[54]. African studies included in this review found that 30 to 38% of participants had 
sub-therapeutic nevirapine Cmin [13, 36, 38, 39]. A  50% nevirapine dose increase to 300 mg 12 hourly 
may therefore be appropriate in African patients, as modelling of South African data suggested [48].  
A Thai study explored increasing nevirapine doses, and randomised 32 Thai patients on rifampicin-based 
TB treatment to receive standard dose (nevirapine 200 mg once daily for 14 days, then 200 mg twice 
daily); or high dose nevirapine (200 mg twice daily followed by 300 mg twice daily) [10]. However, this 
study was stopped by the Drug Safety Monitoring Board (DSMB) because 4 patients in the high dose 
group and 1 in the standard dose group developed hypersensitivity reactions. Little clinical detail 
regarding the hypersensitivity reactions is given, and it is unclear why the DSMB stopped the study, as 
the difference in proportion with hypersensitivity in the 2 groups is not significant (Fishers exact p value 
(calculated from the data) = 0.33). Thai patients have smaller body weights and higher nevirapine 
concentrations than African patients so any risk of adverse re ctions with higher doses may not apply to 
African patients.  To date, no African studies have been conducted exploring safety and efficacy of 
nevirapine administered at a dose of 300 mg daily in patients treated with rifampicin-based TB 
treatment. Such a study is needed to inform clinical practice. It is possible that different dosing 
guidelines might be needed for different populations, because of differences in important covariates 
such as weight and pharmacogenetic factors. 
Contribution of pharmacogenetic factors to variability in changes in nevirapine 
pharmacokinetics in the presence of rifampicin-based TB treatment 
There is variability between individuals in the magnitude of the change in nevirapine concentrations 
when administered with rifampicin-based TB treatment. Pharmacogenetic factors such as CYP 
isoenzyme polymorphisms are likely to play a role in the variability observed.  The CYP2B6 516G>T 
single nucleotide polymorphism, which is common in African patients, results in impaired 2B6 function, 
and other isoenzyme pathways are likely to predominate in nevirapine elimination in individuals who 
are TT homozygotes. Nevirapine concentrations were paradoxically  higher with rifampicin-based TB 
treatment than without  in Thai CYP2B6 G>T single nucleotide polymorphism TT homozygotes [45]. 
Polymorphisms which result in impaired CYP isoenzyme function may alter the predominant CYP 
isoenzyme utilised for drug elimination. Polymorphisms may therefore determine whether the effect of 
rifampicin or the effect of isoniazid on nevirapine concentrations predominates.  
In addition, acetylator status may contribute to variability. Slow acetylator status is common, and 18% 
of South Africans were found to be slow acetylators [52]. The inhibitory effect of isoniazid on nevirapine 
metabolism via CYP3A may be greater in slow acetylators than fast acetylators.  Further studies are 
needed to explore the combined effect of single nucleotide polymorphisms, and acetylator status. Such 
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studies would need to be adequately powered to reach definitive conclusions, and would ideally need 
to combine pharmacogenetic sampling with sequencing for single nucleotide polymorphisms, 
assessment of acetylator status, and measurement of nevirapine and nevirapine metabolite 
concentrations. 
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Background and objectives: Nevirapine-containing antiretroviral therapy (ART) and rifampicin-based
antitubercular therapy are commonly co-administered in Africa, where nevirapine is often the only
available non-nucleoside reverse transcriptase inhibitor. Rifampicin induces the metabolism of nevira-
pine, but the extent of the reduction in nevirapine concentrations has varied widely in previous
studies. We describe the steady-state pharmacokinetics of nevirapine during and after antitubercular
therapy in South African patients.
Methods: Sixteen patients receiving ART including standard doses of nevirapine were admitted twice
for intensive pharmacokinetic sampling: during and after rifampicin-based antitubercular therapy.
Results: Geometric mean ratios for nevirapine pharmacokinetic parameters during versus after anti-
tubercular therapy were 0.61 [90% confidence interval (CI) 0.49–0.79] for Cmax, 0.64 (90% CI 0.52–0.80)
for area under the curve up to 12 h (AUC0–12) and 0.68 (90% CI 0.53–0.86) for Cmin. Nevirapine Cmin
was subtherapeutic (<3 mg/L) in six patients during antitubercular therapy (one of whom developed
virological failure) and in none afterwards. There was no correlation between rifampicin concentrations
and the degree of nevirapine induction assessed by the proportional change in nevirapine concen-
trations between the two admissions. The ratio of nevirapine AUC0–12 to the AUC0–12 of its 12-hydroxy
metabolite was significantly lower in the presence of antitubercular therapy, consistent with induced
metabolism.
Conclusions: Nevirapine concentrations were significantly decreased by concomitant rifampicin-based
antitubercular therapy and a high proportion of patients had subtherapeutic plasma concentrations.
Further study in African patients is required to determine the implications for treatment outcomes.
Keywords: pharmacokinetics, interaction, 12-hydroxynevirapine
Introduction
Tuberculosis (TB) is the leading cause of morbidity and mortality
in HIV-infected patients in Africa.1 As access to antiretroviral
therapy (ART) expands, a substantial number of patients will
require treatment for TB while receiving ART. Nevirapine-based
combination ART is used extensively in resource-limited set-
tings, where few alternative regimens are available. Nevirapine is
metabolized by cytochrome P450 isoenzymes, predominantly
CYP3A4 and CYP2B6, to the hydroxymetabolites 2-, 3-, 8- and
12-hydroxynevirapine.2 Rifampicin is a key component of anti-
tubercular regimens. Rifampicin induces the metabolism of
many drugs, including nevirapine. Previous pharmacokinetic
studies have shown a variable reduction in nevirapine trough
concentrations with concomitant rifampicin, ranging from 10%
to 68%.3 – 6
The largest studies of the interaction between nevirapine and
rifampicin have been in Thai patients.6,7 Despite some reassuring
data suggesting that more than 86% of Thai patients on conco-
mitant rifampicin-based antitubercular therapy attain therapeutic
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nevirapine concentrations,8 their low body weight and slower
nevirapine clearance9 cast doubt on the generalizability of the
results.
We report the steady-state pharmacokinetics of nevirapine
during and after rifampicin-based antitubercular therapy in a
group of South African patients with HIV-associated TB.
Materials and methods
Study design and setting
HIV-infected adults (18 years) on a combination ART
regimen consisting of two nucleoside reverse transcriptase
inhibitors and nevirapine who were in the continuation phase of
rifampicin-based antitubercular therapy were recruited at a
donor-funded (Me´decins Sans Frontie`res) ART clinic in
Khayelitsha, Cape Town, South Africa. Participants were
admitted for intensive pharmacokinetic blood sampling while
taking rifampicin-based antitubercular therapy, and again 10
days or more after completion of antitubercular therapy.
Nevirapine was administered throughout at standard doses of
200 mg 12 hourly. Rifampicin was dosed at 600 mg 5 days a
week in those weighing 55 kg and 450 mg for those ,55 kg.
An estimated sample size of 16 participants had 80% power
at a 5% level of significance to detect a 25% reduction in nevira-
pine Cmin when administered concomitantly with rifampicin,
calculated based on previously published pharmacokinetic par-
ameters.5 Patients were excluded if they had poor venous access,
a Karnofsky score ,70, known severe renal, hepatic or intestinal
disease (malabsorption or severe diarrhoea), pregnancy, or were
taking any other medication known to have a pharmacokinetic
interactions with nevirapine. Adherence to ART and antitubercu-
lar therapy was assessed by means of self-report, using a struc-
tured questionnaire which recorded any doses of ART or
antitubercular treatment omitted in the 4 days before admission.
Haemoglobin, alanine transaminase (ALT) and albumin were
measured on both admissions. CD4þ lymphocyte counts and
quantitative HIV-1 RNA (viral loads) were obtained from the
participants’ 6 monthly routine monitoring results.
The protocol was approved by the research Ethics Committee
of the University of Cape Town. All participants gave signed
informed consent.
Pharmacokinetic assessment
An observed dose of nevirapine was given and the exact time of
administration recorded. Antitubercular therapy was adminis-
tered together with nevirapine at the first sampling occasion.
Venous blood was collected at 20.5, 0.5, 1, 1.5, 2, 4, 6, 10 and
12 h on both admissions. The exact times of sampling were
recorded. Blood was immediately centrifuged and the plasma
was stored at 2808C until analysis.
Assay methodologies for quantifying nevirapine and
12-hydroxynevirapine were derived from a previously published
method.10 Plasma concentrations of nevirapine were determined
by Liquid Chromatography Mass Spectrometry methods using a
Waters Alliance 2690 High Pressure Liquid Chromatograph
(HPLC) coupled to a Waters/Micromass ZMD single quadrapole
mass spectrometer. The mobile phase consisted of 50% aceto-
nitrile in 4 mM ammonium acetate and 0.1% trifluoroacetic acid.
A 20 by 2.1 mm Hypersil Gold C18 column (Thermo) was used
at a flow rate of 0.3 mL/min. Neostigmine served as internal
standard. Detection in positive ionization mode of nevirapine
was at 276.2 (m/z) and neostigmine at 223.2 (m/z). Acetonitrile
(50 mL) containing 1 mg/L internal standard was added to
20 mL of each sample or control to precipitate protein. Samples
were vortexed for 30 s, centrifuged for 5 min at 750 g and 2 mL
of the supernatant was injected onto the column. The standard
curve was linear in the range 0.2–20 mg/L. The lower limit of
quantification (LLQ) was set at 0.2 mg/L.
Plasma concentrations of 12-hydroxynevirapine were quanti-
fied by tandem mass spectrometry using an Applied Biosystems
API 3200 linear ion trap. HPLC was performed on an Agilent
12000 series instrument using a Gemini C18 3 mm particle size,
50 by 2.1 mm column (Phenomonex). The mobile phase com-
prised 15% acetonitrile and 85% ammonium formate. The flow
rate was 0.3 mL/min and injection volume 5 mL. The following
SRM transitions of [M-H]þ precursor ions to product ions were
selected: 12-hydroxynevirapine m/z 283.2–265.2; physostigmine
(internal standard) m/z 276.3–162.3. The internal standard was
made up to a concentration of 0.5 mg/L in acetonitrile. One
hundred microlitres of plasma was transferred to a 1.5 mL poly-
propylene tube and 300 mL of internal standard solution was
added. After mixing for 10 s, the tube was centrifuged for 5 min
at 750 g. Supernatant (10 mL) was transferred to a new 1.5 mL
tube and 1000 mL of the mobile phase was added; 5 mL was
injected onto the column. The standard curve was linear in the
range 0.025–5 mg/L. LLQ was set at 0.025 mg/L.
Plasma concentrations of rifampicin were determined using
an Applied Biosystems API 2000 tandem mass spectrometer,
using a previously published method.11 The mobile phase con-
sisted of 50% methanol, 20% acetonitrile and 30% formic acid
(0.1%). A 20 by 2.1 mm Hypersil Gold C18 column (Thermo)
was used at a flow rate of 0.3 mL/min. Rifapentine served as
internal standard. Detection of rifampicin in positive ionization
mode was at 823.5–791.5 (m/z) and rifapentine at 877.27–
845.30 (m/z). Acetonitrile (150 mL) containing 1 mg/L internal
standard was added to 50 mL of each sample or control to pre-
cipitate protein. Samples were vortexed for 30 s, and centrifuged
for 5 min at 750 g. Supernatant (2 mL) was injected onto the
column. The standard curve was linear in the range 0.1–30 mg/
L. LLQ was set at 0.1 mg/L.
Quality control samples covering the range of the standard
curve were included with each assay run. Inter- and intra-day
percentage coefficients of variation were ,10% for all controls.
The laboratory is a member of the Association for Quality
Assessment in Therapeutic Drug Monitoring and Toxicology
international inter-laboratory quality control programme.
Observed peak plasma concentration (Cmax), time to peak
plasma concentration (Tmax) and minimum plasma concentration
(Cmin) in the dosing interval were determined by inspection of
individual concentration–time curves. Cmin was defined as the
lowest concentration after Tmax. Non-compartmental analysis
was performed (using WinNonlin version 4, Pharsight
Corporation, Mountain View, CA, USA) to calculate area under
the curve to 12 h (AUC0 – 12) using the linear trapezoidal rule
with linear interpolation and half-life (t1/2). The target minimum
plasma concentration for nevirapine was 3 mg/L, based on the
trough concentration recommended in current antiretroviral
therapeutic monitoring guidelines.12
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Statistical analysis
Statistical analysis was performed using STATA version 9.2
(Stata corp. College Station, TX, USA). Descriptive statistics of
patient characteristics and pharmacokinetic data were summar-
ized using means and standard deviations if normally distribu-
ted, and medians and interquartile ranges if non-normally
distributed. Comparison of participant characteristics, laboratory
results and pharmacokinetic parameters in the presence and
absence of antitubercular therapy was performed using a paired
t-test or Wilcoxon signed rank test. Geometric means and geo-
metric mean ratios with 90% confidence intervals (CIs) were
calculated for Cmax, AUC0 – 12 and Cmin. Spearman’s rank corre-
lation coefficients were calculated to explore correlation between
nevirapine and rifampicin pharmacokinetic parameters.
Results
There were 16 participants (13 women) with a median age of 35
years (IQR 27–39). Median CD4 count closest to the first phar-
macokinetic sampling was 115 cells/mm3 (IQR 63–252).
Twelve participants had World Health Organization stage 4 HIV
disease. All participants were taking an ART regimen compris-
ing nevirapine, lamivudine and either stavudine or zidovudine
throughout. At the time of first pharmacokinetic sampling, all
participants were taking rifampicin and isoniazid, and five par-
ticipants were taking ethambutol. Median duration of ART at
the time of first pharmacokinetic sampling was 165 days (IQR
114–221); 3/16 participants were established on ART before
initiating antitubercular therapy and 13 participants had com-
menced ART during antitubercular therapy. Median time from
completion of antitubercular therapy to the second admission for
intensive sampling was 56 days (IQR 32.5–98.5). ALT was
moderately elevated in 3/16 participants at the first admission
and 4/16 participants at the second admission (less than four
times the upper limit of normal in all instances). One participant
reported having missed a single dose of nevirapine 2 days before
the first admission. All other participants reported 100% adher-
ence in the 4 days prior to both admissions.
Participant characteristics and pharmacokinetic parameters of
nevirapine during and after antitubercular therapy are given in
Table 1. Median weight gain between admissions was 2.5 kg
(IQR 0.1–6.9). When participants were receiving antitubercular
therapy, Cmax, Cmin and AUC0 – 12 were significantly lower.
The mean reduction in nevirapine Cmin in the presence of
rifampicin-based antitubercular therapy was 26.3% (95% CI 6.4–
46.3). Geometric mean ratios for nevirapine pharmacokinetic par-
ameters during versus after antitubercular therapy were 0.61 (90%
CI 0.49–0.79) for Cmax, 0.64 (90% CI 0.52–0.80) for AUC0–12
and 0.68 (90% CI 0.53–0.86) for Cmin.
Nevirapine concentration–time curves during and after anti-
tubercular therapy are shown in Figure 1. Nevirapine Cmin was
subtherapeutic (,3 mg/L) in 6/16 participants taking rifampicin
and in none after antitubercular therapy (Figure 2).
Three participants, with a nevirapine Cmin while on antituber-
cular therapy of 1.3, 5.9 and 6.4 mg/L, respectively, had a
detectable viral load (.400 copies/mL) within 6 months of the
first admission. In all of the other participants, including five
with a Cmin,3 mg/L, viral loads measured during the 6 months
after the first admission were suppressed (,400 copies/mL).
Median (IQR) AUC0 – 12 of 12-hydroxynevirapine was similar
during and after antitubercular therapy at 3.2 mg.h/L (2.5–3.9)
and 3.0 mg.h/L (2.6–4.1), respectively (P ¼ 0.5). However,
there was a significant change in the ratio of nevirapine AUC0 –
12 to the 12-hydroxy metabolite AUC0 – 12, with a median ratio
of 14.7 (IQR 12.1–18.0) in the presence of rifampicin-based
antitubercular therapy and 20.4 (IQR 18.3–25.3) after rifampicin-
based antitubercular therapy (P ¼ 0.0004).
Median rifampicin Cmax was 7.8 mg/L (IQR 5.9–9.6) and
median rifampicin AUC0 – 12 was 34.7 mg.h/L (IQR 26.3–56.6).
There was no evidence of an association between rifampicin
AUC0 – 12 and the proportional change in nevirapine concen-
trations between the two admissions.
Table 1. Participant characteristics and nevirapine pharmacokinetic parameters for 16 participants intensively sampled during and after
rifampicin-based antitubercular therapy
Nevirapine during
rifampicin-based
antitubercular therapy
Nevirapine after
rifampicin-based
antitubercular therapy P valuea
Participant characteristics mean weight kg (SD) 65.8 (16.6) 69.3 (16.0) 0.014*
median albumin g/L (IQR) 40.5 (35–44) 41 (39–45) 0.736**
mean haemoglobin g/dL (SD) 12.1 (0.6) 12.5 (0.5) 0.261*
Pharmacokinetic parameter,
median (IQR)
Cmax mg/L 4.6 (3.9–6.1) 7.5 (5.7–10.2) 0.003**
Cmin mg/L 3.2 (2.8–4.5) 4.4 (3.6–6.9) 0.006**
AUC0 – 12 mg.h/L 42.0 (37.4–60.0) 70.1 (52.9–95.2) 0.005**
t1/2 h 26.2 (18.6–36.6) 21.7 (17.3–29.9) 0.234**
Tmax h 1.4 (1.1–1.8) 1.5 (1.0–1.8) 0.641**
*Paired t-test.
**Wilcoxon signed rank test.
aP values ,0.05 are shown in bold.
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Discussion
We found significant reductions in nevirapine Cmin, Cmax and
AUC0 – 12 in participants while they were taking rifampicin-
based antitubercular therapy. Nevirapine Cmin concentration was
below the recommended lower limit of 3 mg/L in 6/16 (38%)
participants taking antitubercular therapy. Although five of these
six participants had a good short-term virological outcome, this
is nevertheless a worrying finding, as the trough concentration is
the key pharmacokinetic parameter for efficacy.12 We found a
significant decrease in the ratio between the AUC0 – 12 of nevira-
pine and its inactive 12-hydroxymetabolite (produced primarily
by CYP3A42) in the presence of rifampicin-based antitubercular
therapy. This indicates that the change in nevirapine pharmaco-
kinetic parameters is due to enhanced metabolism of nevirapine
by CYP3A4, with increased flux through the metabolic pathway
in the presence of rifampicin. Half of the participants had rifam-
picin peak concentrations lower than the recommended reference
range of 8–24 mg/L. This is in keeping with the findings of two
recent African studies, which showed low rifampicin concen-
trations in a high proportion of TB patients,13,14 which was
associated with HIV infection in one study.13 A previous phar-
macokinetic study found that nevirapine did not affect rifampi-
cin concentrations.5
The reduction in nevirapine trough concentrations with con-
comitant rifampicin has varied widely in previous studies. This
variability is due in part to differing study designs. The largest
reductions of nevirapine trough concentrations of 53%6 and
68%3 were found in HIV-infected patients without TB, who
were receiving rifampicin without other concomitant antituber-
cular therapy. It is likely that the inducing effect of rifampicin is
ameliorated by isoniazid, which is an inhibitor of CYP3A—the
major cytochrome P450 isoenzyme involved in nevirapine
metabolism.15 In addition, CYP2B6 polymorphisms are known
to influence nevirapine pharmacokinetics16,17 and may influence
the magnitude of the inducing effect of rifampicin; thus another
source of variability in study results may be differences in the
frequencies of CYP2B6 polymorphisms in different populations.
Two adequately powered Thai studies conducted in patients
with TB reported reductions of nevirapine trough concentrations
of 15.6%18 and 37.2%,8 which are similar to the 26.3% that we
found. However, the mean trough nevirapine concentrations with
concomitant rifampicin-based antitubercular therapy in the Thai
studies were 5.5 and 5.4 mg/L,8,18 considerably higher than the
3.2 mg/L that we found. The likely explanation for the higher
nevirapine trough concentrations is their lower body weight
(10 kg lower than our patients’ mean weight of 65.8 kg),
given that nevirapine clearance is similar in Thai and South
African patients.9
One approach to compensate for the reduction in nevirapine
concentrations when co-administered with rifampicin is to
increase the nevirapine dose. In an Indian study, a 50% dose
increase, selectively given to a small group of seven patients
who had subtherapeutic trough nevirapine concentrations when
the standard dose was co-administered with rifampicin, resulted
in trough concentrations in the therapeutic range.6 However,
given the variability in nevirapine concentrations, this dosing
strategy may result in very high nevirapine concentrations in
some individuals with resultant toxicity and requires further
study.
The key question is whether the observed reduction in nevira-
pine concentrations with concomitant rifampicin results in an
increased risk of virological failure. A retrospective Spanish
study of 32 patients reported that 74% of patients treated with
concomitant nevirapine- and rifampicin-based antitubercular
therapy attained undetectable viral loads, but there was no
control group.19 A Thai cohort study of 70 patients on
nevirapine-based combination ART and concomitant rifampicin-
based antitubercular therapy found that virological suppression
was similar to a control group,7 with virological suppression
rates remaining similar up to 60 weeks.18 However, as men-
tioned above, Thai patients have lower body weight and higher
trough nevirapine concentrations.
A limitation of our study is that the majority of the patients
are women; there may be sex differences in the pharmacokinetics
of both nevirapine and rifampicin. Although pharmacokinetic
sampling was performed after observed drug dosing, dosing in
the days prior to admission was not directly observed, and adher-
ence cannot be guaranteed. Our study is also not powered to
explore the association between nevirapine trough concentration
and virological outcomes.
In conclusion, concomitant rifampicin-based antitubercular
therapy significantly reduces nevirapine concentrations, and sub-
therapeutic trough nevirapine concentrations occur in a signifi-
cant proportion of patients. Our data together with that from
Figure 1. Nevirapine median concentration–time profile during and after
rifampicin-based antitubercular therapy. Bars represent interquartile ranges.
Figure 2. Nevirapine Cmin in 16 participants during and after rifampicin-
based antitubercular therapy.
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other small studies suggest that virological responses are reason-
able, but there is a need for larger cohort studies, particularly in
sub-Saharan Africa.
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Research protocol 
 
This research protocol included 4 objectives. Objective 1 forms the subject of this research dissertation, 
namely, “to compare nevirapine pharmacokinetics with and without rifampicin-based antitubercular 
therapy, by means of non-compartmental analysis.” 
 
Objectives 2, 3 and 4, and the additional data collected to meet those objectives, formed the basis of 
analyses performed by other investigators. Those analyses are therefore not presented in this research 
report. 
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Introduction 
 
Many HIV-infected patients in sub-Saharan Africa are co-infected with tuberculosis.  
Tuberculosis is a leading cause of morbidity and mortality in HIV-infected South 
Africans1. Antiretroviral access in sub-Saharan Africa is expanding.  Highly active 
antiretroviral therapy (HAART) reduces the incidence of tuberculosis in HIV infected 
patients by more than 80% in Cape Town, South Africa1, but a substantial number of 
patients will still present with active tuberculosis while on antiretroviral therapy(ART).  
 
Treatment of tuberculosis with a rifampicin-based regimen, consisting of rifampicin, 
isoniazid, pyrazinamide and ethambutol (with the addition of streptomycin in patients 
who have previously had an episode of tuberculosis), is standard practice in South 
Africa2.  However, when a patient on HAART is started on treatment for tuberculosis, the 
possibility of clinically significant drug interactions, potentially altering the 
pharmacokinetics of both antiretroviral and antimycobacterial drugs, must be taken into 
account3 4. Interactions between non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), protease inhibitors and rifamycins, as well as additive side effects and 
toxicities must be addressed when managing an HIV infected patient with tuberculosis.   
 
Rifampicin is a potent inducer of cytochrome P450, isoenzyme 3A4. This results in 
enhanced drug metabolism and may lead to sub-therapeutic concentrations of non-
nucleoside reverse transcriptase inhibitors and many protease inhibitors.5 Nevirapine is 
metabolized by cytochrome P450, by isoenzymes 3A4 and also acts as an inducer of 
cytochrome P450 3A45, 6.   
 
An antiretroviral regimen consisting of 2 nucleoside reverse transcriptase inhibitors 
(NRTIs), and either efavirenz or nevirapine, is the recommended first line ART regimen 
by the World Health Organisation for resource-limited settings and has been 
implemented in South Africa.  Nevirapine-based ART is the 1st line regimen of choice in 
South Africa in women of reproductive potential who cannot guarantee contraception, 
because of the teratogenic potential of efavirenz. Nevirapine is a component of 
inexpensive generic twice-daily fixed dose ARV combinations that are used extensively 
in the developing world. Fixed dose combination therapy is likely to be widely 
implemented as it improves adherence. In sub-Saharan Africa, the high disease burden 
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of both HIV and tuberculosis means that many patients will require concurrent treatment 
with rifampicin and nevirapine. 
 
There is limited data on the interaction between nevirapine and rifampicin. An 
underpowered pharmacokinetic study in 5 Spanish patients7 treated with both nevirapine 
and rifampicin showed a 31% decrease in area under the curve (AUC), a 31% decrease 
in Cmax and a 21% decrease in Cmin, which was not statistically significant. Another study 
in 22 patients showed a 68% reduction in the clearance of nevirapine in the presence of 
rifampicin in comparison to historical controls.15  
 
An observational study of 36 patients in Spanish hospitals treated with nevirapine and 
rifampicin showed good virological response in co-treated patients.  However, 8 patients 
(22%) in this cohort developed significant toxicity, leading to discontinuation of one or 
both drugs in 5 patients. 4 patients developed hepatitis, which was thought to be due to 
rifampicin, and 4 patients presented with adverse effects thought to be due to nevirapine 
(1 rash, 1 rash with hepatitis, and 2 gastrointestinal disturbances).8    
 
The recently updated Center for Disease Control and Prevention (CDC) guidelines 9 for 
treatment of tuberculosis in HIV-infected patients state that a regimen comprising of 
nevirapine and 2NRTIs may be used with rifampicin, although they comment that this is 
supported by limited data. The Western Cape antiretroviral treatment protocol gives the 
option of switching nevirapine to efavirenz when tuberculosis is diagnosed and anti-
tuberculous treatment commenced, or continuing nevirapine with monthly liver function 
monitoring.10   
 
Data from a population pharmacokinetic study of nevirapine11 suggests that there may 
genetic variability in nevirapine clearance between ethnic groups. There are few data 
about the pharmacokinetics of nevirapine in South African patients, and the 
pharmacokinetics of nevirapine and rifampicin, when administered concomitantly, has 
not been studied in our population.  There is no published data about the 
pharmacokinetics of isoniazid when administered with nevirapine. There is high inter-
individual and inter-occasional variability in rifampicin kinetics, and the extent of 
exposure to rifampicin may be a determinant of the extent of rifampicin-inducible 
CYP3A4 expression12  
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More information about the pharmacokinetic interaction between nevirapine and 
rifampicin, and the impact of this interaction on treatment efficacy and adverse reactions 
in South African patients is urgently needed.  The impact on pharmacokinetics of 
covariates such as gender is (known to be important determinant of pharmacokinetics 
for several drugs), body mass index, concomitant medication (including over the counter 
and herbal remedies) concomitant recreational substance use or abuse and concomitant 
illness needs to be explored. 
 
In addition to non-compartmental analysis, a population approach using nonlinear 
mixed-effect modeling will be used in this study. This approach allows the use of sparse 
sampling to predict individual pharmacokinetic measures from a structural model 
describing the drug’s pharmacokinetics in the population. Furthermore, it is a powerful 
tool to account for the pharmacokinetic effect of measured covariate factors (fixed 
effects) and random (unexplained) effects which together comprise intra- and inter-
subject pharmacokinetic variations13,14.  
 
Pharmacokinetic assessments are limited by the need to transport blood samples in a 
good condition to the laboratory. This must be done rapidly or by freezing the samples. 
This is impractical and expensive. During this study a method will be validated for 
determining nevirapine concentrations on dried blood spots that can be stored and 
transported inexpensively.  
 
 Study aim 
 
 To describe nevirapine pharmacokinetic parameters in South African HIV-infected 
patients taking nevirapine based antiretroviral therapy, in the continuation phase of 
rifampicin- based short course chemotherapy.  
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Study objectives 
In South African HIV infected patients taking nevirapine-based antiretroviral therapy: 
1. To compare nevirapine pharmacokinetics with and without rifampicin, by 
means of non-compartmental analysis 
2. To build pharmacokinetic models describing nevirapine (with and without 
concomitant rifampicin and isoniazid), rifampicin and isoniazid in HIV-infected patients 
on nevirapine-based antiretroviral therapy, using a population approach.  
3. To validate a whole blood method for measurement of nevirapine 
concentrations, using 0.2mL blood samples dried onto filter paper 
4. To assess the influence of patient factors, such as gender, weight, alcohol 
consumption, smoking, body mass index (BMI), ALT, albumin, total bilirubin, 
haemoglobin and disease stage on the pharmacokinetic parameters of nevirapine, 
isoniazid and rifampicin. 
 
Methodology 
Design 
This study has a cross-sectional, and a repeated cross-sectional component, including 
both intensive and sparse pharmacokinetic sampling. 
Intensive sampling 
• Between 16 and 27 subjects (Group A- intensive), who are on a ART regimen 
consisting of 2 NRTIs and n virapine 200mg 12 hourly, and in the continuation phase of 
tuberculosis therapy, will be recruited sequentially. They will be admitted for 
pharmacokinetic blood sampling. 
• Not less than 14 days after completion of tuberculosis treatment, the same 16 to 
27 subjects will be admitted again for PK sampling.  
• During the 1st admission, pharmacokinetic profiles of nevirapine, rifampicin and 
isoniazid will be determined on each subject  
• During the 2nd admission, the pharmacokinetic profile of nevirapine without 
rifampicin and isoniazid will be determined. 
• 10 participants who have been taking nevirapine for at least 3 weeks, and are not 
on rifampicin (Group B-intensive) will be recruited for intensive sampling to characterize 
the nevirapine pharmacokinetic profile 
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Patients will be admitted for 24 hours for all admissions.  Nevirapine is dosed 12 hourly.  
Serial blood sampling to 24 hours will allow for sampling of nevirapine concentrations 
across 2 dosing intervals and assessment of interoccasional variability. During the 1st 
admission for Group A, rifampicin and isoniazid concentrations will be measured in 
samples taken during the1st 12 hours. 
Sparse sampling 
• Additional participants (Group A-sparse) will be recruited to make up a total 
sample size of 27 in Group A including intensively and sparsely sampled participants).  
Participants who are on an antiretroviral regimen consisting of 2 NRTIs and nevirapine 
200mg 12 hourly, and in the continuation phase of tuberculosis therapy, will be recruited 
at their routine clinic visit.  Exact time of last doses of nevirapine and TB treatment will 
be recorded, and 2 blood samples will be taken not less than 1 hour apart, for 
determination of nevirapine, rifampicin and isoniazid concentrations.  
• In the same patients, nevirapine concentrations will be determined in two 
blood samples, not less than 1 hour apart, collected at a routine clinic visit at least 14 
days after completion of TB treatment. 
•  17 patients (Group B-sparse) who have been treated for at least 3 weeks on 
nevirapine, but are not being treated for tuberculosis will be recruited at their routine 
clinic visit.  Exact time of last dose of nevirapine will be recorded, and 2 blood samples 
will be taken not less than 1 hour apart,  
 
Data from both intensively and sparse sampled patients will be used to create a 
structural model for nevirapine, rifampicin and isoniazid.(using nonlinear mixed effects 
methods) 
 
Sample size justification 
The sample sizes required are based on the Cmin values published by Ribera et al.7  
Sample size for non-compartmental analysis: 
Parametric assumptions are used and estimates are powered to detect a 25% reduction 
in nevirapine Cmin when given with rifampicin (power 0.8; alpha 0.05; one sided t-tests.) 
Should the correlation between the Cmin with rifampicin and the Cmin without rifampicin be 
0.2, and the correlations between the 2 profile measurements generated with rifampicin 
and those generated without rifampicin are each 0.5, we require 16 participants to 
complete intensive PK sampling on both occasions. This sample size was calculated 
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using a paired t test, using the mean difference and the standard deviation of the mean 
difference [sqrt((sd1*sd1)+(sd2*sd2)-(2*0.25*sd1*sd2))] 
 
Sample size for population modeling: 
Parametric assumptions are used and estimates are powered to detect a 25% reduction 
in nevirapine  Cmin when given with rifampicin (power 0.9; alpha 0.05; one sided t-tests).   
 
Repeated cross-sectional component (Group A – intensive+sparse):  
Should the correlation between the Cmin with rifampicin and the Cmin without rifampicin be 
0.2, and the correlations between the 2 profile measurements generated with rifampicin 
and those generated without rifampicin are each 0.5, we require 22 participants to 
complete PK sampling on both occasions. This sample size was calculated using a 
paired t test, using the mean difference and the standard deviation of the mean 
difference [sqrt((sd1*sd1)+(sd2*sd2)-(2*0.25*sd1*sd2))] 
 
We have therefore chosen a sample size of 27 participants treated with nevirapine and 
in the continuation phase of tuberculosis treatment (Group A), to allow for a 25% loss to 
follow-up in this group.  
 
Cross-sectional component (Group B):  
A t-test for independent samples was used and a correlation of 0.5 was assumed 
between the 2 measurements in Group A and the 2 measurements in group B 
respectively, to determine the number of patients in group B needed for comparison of 
the nevirapine Cmin to that of Group A with rifampicin (27 patients). To detect a 25% 
reduction nevirapine Cmin of the latter group, Group B should comprise 27 patients (alpha 
0.05; power 0.9).   
  
 
 
Site 
Participants will be recruited at the antiretroviral treatment site at the Site B, Khayelitsha 
community health centre in Cape Town, South Africa. The intensive sampling 
component of the study will require 2 overnight admissions to the Division of 
Pharmacology PK ward. 
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Subjects 
Group A  
Inclusion criteria 
• HIV-infected  
• On an antiretroviral regimen consisting of nevirapine 200mg 12 hourly and 2 
NRTIs 
• In the continuation phase of standard tuberculosis treatment 
• >18 years  
• Able to give informed consent 
 
Exclusion criteria 
• Poor venous access 
• Karnofsky score<70 
• Known severe renal, hepatic or GIT disease 
• Malabsorption or severe diarrhoea 
• Other medication that may (on the basis a known interaction, or  a strong 
theoretical  basis) affect nevirapine, rifampicin or INH concentrations.  
 
Group B 
Inclusion criteria 
• HIV-infected  
• On an antiretroviral regimen consisting of nevirapine 200mg 12 hourly and 2 
NRTIs 
• >18 years  
• Able to give informed consent 
 
Exclusion criteria 
• Poor venous access 
• Karnofsky score<70 
• Known severe renal, hepatic or GIT disease 
• Malabsorption or severe diarrhoea 
• Other medication that may (on the basis a known interaction, or  a strong 
theoretical  basis) affect nevirapine, rifampicin or INH concentrations.  
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Subject Restrictions for intensive sampling group (Group A-intensive): 
Medicines:   No use of any new medication, including over-the-counter, and herbal 
remedies, without discussion with the principal investigator, from 14 days before the 1st 
admission to completion of sampling. 
Diet:  Standardised meals to be given during admissions for PK sampling 
Movement:  Subjects will be admitted at 8am and will be required to stay in the ward 
until completion of blood sampling the following morning  
Adherence: Adherence over the week prior to admission will be assessed by means of 
a questionnaire and pill-count from pill box. Pillbox will be filled at the MSF clinic 1 week 
before admission 
 
Ethical considerations 
This study will be conducted according to the guidelines of the Helsinki declaration of 
2000 and according to the ICH principles of Good Clinical Practise. Approval of the 
protocol and informed consent documents will be sought from the research ethics 
committee of the University of Cape Town before commencing with the study.   
All protocol amendment shall be submitted to the UCT ethics committee for approval.  
The ethics committee will be notified of all protocol deviations, and will be notified of any 
serious adverse event within 72 hours.  All patient data will be treated in the strictest 
confidence.  A record of all adverse events will be retained.  Patients in the intensively 
sampled group will be remunerated for inconvenience.  The remuneration amount will be 
R150 per admission.  No remuneration will be given to the sparsely sampled group. 
 
Data Collection: 
The following information will be obtained from the patient’s previous records: last CD4 
count and viral load, and date.   
The following information will be collected at baseline: age, weight, height, gender, race, 
WHO clinical stage, duration of antiretroviral therapy, alcohol / recreational drugs/ 
cigarettes consumption history, concomitant medication, other diseases, time of last food 
consumption, and details of food consumed. 
 
The following will be performed at each sampling occasion:  
• ALT, albumin and total bilirubin 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
43 
 
• Laboratory haemoglobin 
• Completion of questionnaire about side effects  
• Completion of a questionnaire about adherence 
• Pill-count  
 
Subjects will be assigned sequential numbers on enrolment.  
 
Analytical methods 
Sample collection 
Venous blood will be collected in 4 ml LiH Pst Gel plastic vacuum tubes, stored on ice 
until sample collection at that time point is complete for all patients, then immediately 
centrifuged for ten minutes at 3 000 rpm.  Plasma will be transferred to labelled 1.2 ml 
microcentrifuge tubes, which will be stored at -80°C until analysis (The label on each 
tube will include the subject number, the visit (1 or 2 ) and the sampling time  
Total volume of blood drawn throughout the entire study period in the intensively 
sampled group (minimum 6 weeks duration): 200 mL.  No more than 70 mL of blood will 
be drawn at any one admission. 
A method is being developed whereby the nevirapine, rifampicin and isoniazid 
concentrations will be determined using a 200 μl whole blood sample dried onto filter 
paper and stored at room temperature in a sealed plastic bag with desiccant. The 
method will be convenient for the scant pharmacokinetic sampling under field conditions. 
The method will be validated using a small portion from each blood sample collected. 
Pharmacokinetic profiling 
Patients enrolled in “Group A- intensive” will be admitted in the morning to the Division of 
Pharmacology’s PK ward at 8am.  At 9am, enrolled patients will receive their morning 
dose of nevirapine, together with the morning dose of NRTIs. Standard meals will be 
given during the day. 
Drugs will be administered with 200ml of water, and the exact time of administration 
recorded.  The investigator or an assistant will directly observe drug ingestion.   
Blood samples will be taken at approximately the following time points and the exact 
time of sampling will be recorded: 
1st admission: 0, 0.5, 1, 1.5, 2, 4, 6, 10, 12, 12.25, 12.75, 14, 22 and 24 hours.   
Nevirapine will be determined in all samples; rifampicin an isoniazid will be determined 
from 0-12 hours 
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Pharmacokinetic sampling will be repeated a 2nd time to measure nevirapine 
concentrations, 14 days or more after rifampicin and isoniazid have been discontinued. 
The sampling schedule will be as follows 
2nd admission:  0, 0.5, 1, 1.5, 2, 4, 6, 10, 12, 12.25, 12.75, 14, 22 and 24 hours. 
“Group A-scant” and “Group B” participants will be sampled twice (at least 1 hour apart) 
at each pharmacokinetic sampling, which will be performed at a routine clinic visit as 
described previously.  
For each sample a 0,2 ml whole blood sample will be collected onto filter paper and 
dried before storage (at room temperature) in a sealed plastic bag with desiccant These 
samples will be used to validate the “dried whole blood” methodology for assessment of 
nevirapine concentrations.  
 
Sample analysis 
Assays for determination of nevirapine, rifampicin and isoniazid plasma concentrations 
(from plasma samples (intensively sampled participants) and dried blood spots (all 
samples) will be performed using validated Liquid Chromatography Mass Spectrometry 
(LCMS) methods in the Division of Pharmacology Laboratory.  
 
Validation of dried whole blood methodology for measurement of nevirapine 
concentrations 
Results obtained from dried whole blood will be compared with results obtained from 
plasma,, in order to validated the dried whole blood methodology 
 
Statisical analysis 
 
Statistical methods 
Group A-intensive:  Noncompartmental analysis will be performed to calculate the 
following parameters for each drug taken on each occasion, using WinNonlin Enterprise 
version 4 : 
• Plasma peak concentration (Cmax)  
•  Time to plasma peak concentration (Tmax) 
• Apparent half-life (t1/2) 
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• Area under the plasma concentration-time curve from 0 until 12 hours for 
nevirapine, and from 0-24 hours for rifampicin and isoniazid (AUCt 0-24) and from 0 - ∞ 
(AUCi) 
• Plasma trough concentration (Cmin)  
The whole blood drug concentrations from all patients will be used in a population 
analysis. The structural models for each drug will be derived (in the first instance using 
concentrations from the intensively sampled participants), allowing the prediction of the 
PK measures for the participants undergoing scant sampling. In addition, the effect of 
the covariate factors and the coadministration of the TB drugs on the models will be 
assessed.  
The primary objective will be to compare the PK measures of N (AUC, Cmax, Cmin) 
between those patients receiving concomitant R and H, and those receiving N without 
TB treatment. Appropriate nonparametric or parametric tests will used to determine the 
differences between the groups. 
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Patient information sheet: Pharmacokinetics of nevirapine in HIV infected patients in South 
Africa, taking nevirapine with and without rifampicin. 
Investigators 
Dr Karen Cohen (phone 021 406 6778), University of Cape Town 
Dr Gilles Van Cutsem (phone 021 361 4575), Médecins Sans Frontières 
Prof Gary Maartens, Dr Helen McIlleron, Prof Peter Smith, Dr Andrew Boulle, Chelsea Morroni 
University of Cape Town 
Dr Eric Goemaere Médecins Sans Frontières 
 
You are being invited to participate in a study looking at nevirapine blood levels in HIV infected people, some of 
whom are being treated for tuberculosis (TB). 
 
Why are we doing this study? 
Tuberculosis is a common and important problem among people with HIV infection. People who get tuberculosis 
are treated with a combination of medicines, including one called rifampicin. Rifampicin can have an effect on 
other medicines that a person is taking at the same time, such as some medicines that fight HIV (antiretroviral 
medicines), by making the body break down the other medicines more quickly. It is possible that rifampicin could 
affect the antiretroviral drug nevirapine in this way. This is important because if antiretroviral medicines are 
broken down more quickly than normal, they may not work as effectively as they should. There is at present little 
information about blood levels of nevirapine in HIV infected people in South Africa, and little information about 
what happens to nevirapine levels when HIV infected people are treated with rifampicin.  We are carrying out this 
study to find out more about these questions, and we invite you to take part in it. 
This study will not benefit you right now, but the results of the study will help doctors to choose the best 
combination of antiretroviral medicines to give people with HIV infection who get tuberculosis, and so will help 
people like you in the future.   
If you have any questions about this study, please ask us. You do not have to take part in this study: if you do not 
take part, it will not affect the medical care you receive. You can decide to stop taking part in the study at any 
time, without giving a reason, and without affecting your future medical care. 
 
If you take part in this study, what will happen? 
Sparse sampling group: 
If you agree to take part in this study, we will ask you some questions about your health, and all the medicines 
you are taking today and those you have taken in the last two weeks. We will look at your hospital and clinic 
records to check details of illnesses you have had previously, recent medicines, and the results of routine blood 
tests. We will measure how tall you are, and record your weight. Blood will be taken twice, at different times not 
less than 1 hour apart, on the day that you visit the clinic.  We will take 16mL (about 4 teaspoons) of blood for 
the study and test it to see how much of the antiretroviral drug nevirapine, and the antituberculosis drugs 
rifampicin and isoniazid, are in it, as well as testing your liver function and haemoglobin. 
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(this paragraph is only for people with TB currently taking rifampicin) 
We would like to take a second 4 samples of blood (totaling 16mL or about 4 teaspoons) from you when your 
tuberculosis treatment has been finished for at least 2 weeks. This will also be tested to see how much 
nevirapine is in it, as well as your liver function and haemoglobin. 
Intensively sampled group  
If you agree to take part in this study and enter the intensively sampled group, we will ask you some questions 
about your health, all the medicines you are taking today and those you have taken in the last two weeks. We 
will look at your hospital and clinic records to check details of illnesses you have had previously, recent 
medicines, and the results of routine blood tests. We will measure how tall you are, and record your weight. 
Blood will be taken to check your liver function and haemoglobin.   You will be admitted to a hospital ward 2 
times, for a period of 24 hours at each occasion.  The 2nd sampling admission will occur 4 weeks or more after 
you have completed all your treatment for tuberculosis. 
During the admissions a venous cannula (like a drip) will be inserted into a vein, and blood will be taken from 
you at set time points 
Blood samples will be taken at the following time points: 
1st admission (after your swallow your morning dose of nevirapine and TB treatment): 0, 0.5, and 1, 1.5, 2, 4, 6, 
10, 12, 12.25, 12.75, 14, 22 and 24 hours.    
2nd admission (after your swallow your morning dose of nevirapine):  0, 0.5, 1, 1.5, 2, 4, 6, 10, 12, 12.25, 12.75, 
14, 22 and 24 hours 
 
A total volume of no more than 70mL (5 tablespoons) of blood will be taken at each admission.  This blood will 
be used to measure the concentrations of the drugs nevirapine, rifampicin and isoniazid.  In addition, at each 
visit, tests will be done to check your liver function and haemoglobin, and you will be asked about any side 
effects of your medicine.  You will also be asked about your compliance with your medication. 
 
Confidentiality of information collected during this study 
All information collected during the course of this study will be kept securely and confidentially: Dr Cohen and Dr 
Van Cutsem are responsible for this.  Reports about the study and results that may be published in scientific 
journals will not include any information which identifies you personally.  
 
The committee giving ethical approval for this study  is the University of Cape Town Ethics committee.  If you 
have any problem with this study please contact the Ethics committee directly, telephone 
number___________________ 
 
(This document will be available in the most frequent local languages and will be read by, read to or translated to 
the participant.) 
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Patient consent form: Nevirapine mid-dosing interval plasma levels in HIV infected patients in 
South Africa, taking nevirapine with and without rifampicin. 
 
I have fully understood the above information about this study, which I have read, or which has been read or 
translated to me.  I understand what will be required of me if I take part in the study. 
 
My questions concerning this study have been answered by ……………………………............ 
                                                                                                (name of study staff member) 
 
I agree to take part in the study:                   YES  /  NO    (answer to be circled) 
 
I understand that I may withdraw from this study at any time without giving a reason and without affecting my 
normal care and management. 
 
Participant’s signature: ………………………………….  Date: ……………….. 
Participant’s name: …………………………………….…………………………………... 
 
If the information sheet and consent form were translated or explained to the participant, please enter the name 
of the translator here and their signature: 
 
Translator’s signature: ………………………………….  Date: ……………….. 
Translator’s name: ………………………………………………………………………… 
 
If the participant gave verbal consent, please enter the name of the person who witnessed the consent here and 
their signature: 
Witness’ signature: ……………………………………..  Date: ……………….. 
Witness’ name: …………………………………………………………………………….. 
 
Name and signature of investigator or designated co-investigator taking consent 
Investigator Signature: ……………………………………..  Date: ……………….. 
 
Investigator Name: …………………………………………………………………………….. 
